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ABSTRACT

Provided are monoquaternary ammonium compounds which
are modulators of nicotinic acetylcholine receptors. Also
provided are methods of using the compounds for modulating the function of a nicotinic acetylcholine receptor, and for
the prevention and/or treatment of central nervous system
disorders, substance use and/or abuse, and gastrointestinal
tract disorders.
10 Claims, No Drawings
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MONO QUATERNARY AMMONIUM SALTS
AND METHODS FOR MODULATING
NEURONAL NICOTINIC ACETYLCHOLINE
RECEPTORS

central nervous system are the homomeric receptors labeled
by [3 H]methyllycaconitine (MLA), which has high affinity
for the a7 nicotinic receptor subtype. Nicotinic receptor
subtypes can be studied using functional assays, such as
NIC-evoked neurotransmitter release (e.g., [3 H]dopamine
(DA) release, [3 H]norepinephrine (NE) release, [3 H]serotonin (5-HT) release, [3 H]garmna-aminobutyric acid
(GABA) release and [3 H]glutamate release) from superfused rat brain slices. Nicotinic receptors are located in the
cell body and terminal areas of these neurotransmitter systems. NIC facilitates neurotransmitter release from nerve
terminals.
The structural and functional diversity of central nervous
system nicotinic receptors has stimulated a great deal of
interest in developing novel, subtype-selective agonists and/
or antagonists. Some of these agonists are currently being
evaluated in clinical trials for cognitive enhancement and
neuroprotective effects, potentially beneficial for disease
states such as Alzheimer's and Parkinson's disease.

5

CROSS REFERENCE TO RELATED
APPLICATION
This application is a divisional of U.S. application Ser.
No. 12/304,955, which is a National Stage ofPCTIUS2007/
014192, filed on Jun. 15, 2007, which claims benefit of U.S.
Provisional Application No. 60/814,423, filed Jun. 16, 2006,
which are expressly incorporated herein by reference herein.
IDENTIFICATION OF FEDERAL FUNDING
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The present invention was supported by Grant NIH
U19DA017548 from the National Institutes of Health, and
therefore the govermnent may have rights in the invention.
20

FIELD OF THE INVENTION

SUMMARY OF THE INVENTION

The invention relates to monoquatemary armnonium salts
and their use in modulating nicotinic acetylcholine receptors.

In one embodiment, compounds corresponding to the
following structure are provided.
25

BACKGROUND OF THE INVENTION
S(-)-nicotine (NIC) activates presynaptic and postsynaptic neuronal nicotinic receptors that evoke the release of
neurotransmitters from presynaptic terminals and that
modulate the depolarization state of the postsynaptic neuronal membrane, respectively. Thus, nicotine produces its
effect by binding to a family of ligand-gated ion channels,
stimulated by acetylcholine (ACh) or nicotine which causes
the ion channel to open and cations to flux with a resulting
rapid (millisecond) depolarization of the target cell.
Neuronal nicotinic receptors are composed of two types
of subunits, a and ~' and assemble as heteromeric receptors
with the general stoichiometry of 2a and 3~ or as homomeric receptors with Sa subunits. Nine subtypes of the a
subunit (a2 to a10) and three subtypes of the~ unit (~2 to
~4) are found in the central nervous system. The most
common nicotinic receptor subtype in the brain is composed
of two a4 and three ~2 subunits, i.e., a4~2. These subunits
display different, but overlapping, patterns of expression in
the brain. Examples of heteromeric receptor subtypes
include a4~2, a3~2, a3~4, a6~2, a4a5~2, a6a5~2,
a4a6~2, a4~2~4, a3~2~4, and others. The predominant
homomeric subtype includes a7, but other combinations
have also been proposed.
For the most part, the actual subunit compositions and
stoichiometries of nicotinic receptors in the brain remain to
be elucidated. Thus, neuronal nicotinic receptor subtype
diversity originates from differences in the amino acid
sequence at the subunit level and from the multiple combinations of assemblies of subunits into functional receptor
proteins, which affords a wide diversity of pharmacological
specificity.
In spite of the extensive diversity in neuronal nicotinic
receptor messenger RNA expression, only a limited number
of tools are available to study the pharmacology of native
receptors. Radioligands are used in many studies. [3 H]NIC
appears to label the same sites in the brain as [3 H]ACh. It has
been estimated that over 90% of [3 H]NIC binding in the
brain is due to association with the heteromeric receptor that
is composed of a4 and ~2 subunits. Also abundant in the
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A 1 , A 2 , A 3 , A 4 , and A 5 are independently selected from
nitrogen or carbon, provided that when nitrogen is present,
the nitrogen does not have an R substituent attached.
R 1 , R 2 , R 3 , R4 , and R 5 are each independently selected
from the group consisting of hydrogen, alkyl, substituted
alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted
alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl,
heterocycle, substituted heterocycle, halo, cyano, and nitro,
orR 1 and R 2 orR2 and R 3 together with the carbons to which
they are attached independently form a three to eightmember cycloalkane, substituted cycloalkane, cycloalkene,
substituted cycloalkene, aryl, substituted aryl, heterocycle
with one to three hetero atoms in the ring, or substituted
heterocycle with one to three hetero atoms in the ring.
Z 1 is absent or is selected from the group consisting of
alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl,
alkenyl, substituted alkenyl, alkynyl, substituted alkynyl,
phenylene, substituted phenylene, alkoxy, and substituted
alkoxy.
Z 2 is selected from the group consisting of alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, arylene, substituted arylene, heterocycle, substituted heterocycle,
alkoxy, and substituted alkoxy.
Z 3 is selected from is selected from hydrogen, alkyl,
substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl,
substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heterocycle, and substituted heterocycle.
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x- is an inorganic or organic anion.
In another embodiment, a composition is provided comprising a pharmaceutically acceptable carrier and a compound as described above.
In another embodiment, a method is provided for selectively modulating the function of a nicotinic acetylcholine
receptor comprising administering a therapeutically effective amount of a compound as described above to a mammalian subject in need thereof.
In another embodiment, a method is provided for preventing and/or treating a central nervous system associated
disorder comprising administering a therapeutically effective amount of a compound as described above to a mammalian subject in need thereof.
In another embodiment, a method is provided for preventing and/or treating substance use and/or abuse comprising administering a therapeutically effective amount of a
compound as described above to a mammalian subject in
need thereof.
In another embodiment, a method is provided for preventing and/or treating gastrointestinal tract disorders comprising administering a therapeutically effective amount of a
compound as described above to a mammalian subject in
need thereof.
Other methods, features and advantages of the present
invention will be or become apparent to one with skill in the
art upon examination of the following detailed descriptions.
It is intended that all such additional methods, features and
advantages be included within this description, be within the
scope of the present invention, and be protected by the
accompanying claims.

The term "agonist" refers to a substance which interacts
with a receptor and increases or prolongs a physiological
response (i.e. activates the receptor).
The term "partial agonist" refers to a substance which
interacts with and activates a receptor to a lesser degree than
an agonist.

10

The terms "disorder," "disease," and "condition" are used
inclusively and refer to any status deviating from normal.
15

20
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The term "central nervous system associated disorders"
includes any cognitive, neurological, and mental disorders
causing aberrant or pathological neural signal transmission,
such as disorders associated with the alteration of normal
neurotransmitter release in the brain.
The term "lower alkyl" refers to straight or branched
chain alkyl radicals having in the range of 1 to 4 carbon
atoms.
The term "alkyl" refers to straight or branched chain alkyl
radicals having 1 to 19 carbon atoms, and "substituted alkyl"
refers to alkyl radicals further bearing one or more substituents including, but not limited to, hydroxy, alkoxy (of a
lower alkyl group), mercapto (of a lower alkyl group), aryl,
heterocyclic, halogen, trifluoromethyl, cyano, nitro, amino,
carboxyl, carbamate, sulfonyl, and sulfonamide.

30

The term "cycloalkyl" refers to cyclic ring-containing
moieties containing 3 to 8 carbon atoms, and "substituted
cycloalkyl" refers to cycloalkyl moieties further bearing one
or more substituents as set forth above.

35

The term "alkenyl" refers to straight or branched chain
hydrocarbyl groups having at least one carbon-carbon
double bond and having 2 to 19 carbon atoms, and "substituted alkenyl" refers to alkenyl groups further bearing one or
more substituents as set forth above.

40

The term "alkynyl" refers to straight or branched chain
hydrocarbyl moieties having at least one carbon-carbon
triple bond and having 2 to 19 carbon atoms, and "substituted alkynyl" refers to alkynyl moieties further bearing one
or more substituents as set forth above.

DETAILED DESCRIPTION OF THE
INVENTION
Before the present compositions and methods are
described, it is to be understood that the invention is not
limited to the particular methodologies, protocols, assays,
and reagents described, as these may vary. It is also to be
understood that the terminology used herein is intended to
describe particular embodiments of the present invention,
and is in no way intended to limit the scope of the present
invention as set forth in the appended claims.
It must be noted that as used herein and in the appended
claims, the singular forms "a," "an," and "the" include plural
references unless the context clearly dictates otherwise.
Unless defined otherwise, all technical and scientific
terms used herein have the same meanings as commonly
understood by one of ordinary skill in the art to which this
invention belongs. All publications cited herein are incorporated herein by reference in their entirety for the purpose
of describing and disclosing the methodologies, reagents,
and tools reported in the publications that might be used in
connection with the invention. Nothing herein is to be
construed as an admission that the invention is not entitled
to antedate such disclosure by virtue of prior invention.
The term "nicotinic acetylcholine receptor" refers to the
endogenous acetylcholine receptor having binding sites for
acetylcholine which also bind to nicotine. The term "nicotinic acetylcholine receptor" includes the term "neural nicotinic acetylcholine receptor."
The terms "subtype of nicotinic acetylcholine receptor,"
and "nicotinic acetylcholine receptor subtype" refer to various subunit combinations of the nicotinic acetylcholine
receptor, and may refer to a particular homomeric or heteromeric complex, or multiple homomeric or heteromeric
complexes.

The term "antagonist" refers to a substance which interacts with and decreases the extent or duration of a physiological response of that receptor.

45

The term "aryl" refers to aromatic groups having 6 to 24
carbon atoms, and "substituted aryl" refers to aryl groups
further bearing one or more substituents as set forth above.
50
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The term "heterocyclic" refers to cyclic moieties containing one or more heteroatoms as part of the ring structure and
having 3 to 24 carbon atoms, and "substituted heterocyclic"
refers to heterocyclic moieties further bearing one or more
substituents as set forth above.
The term "halogen" refers to fluoride, chloride, bromide
or iodide groups. It is understood that in all substituted
groups defined above, polymers arrived at by defining
substituents with further substituents to themselves (e.g.
substituted aryl having a substituted aryl group as a substituent which is itself substituted with a substituted aryl
group, etc.) are not intended for inclusion herein. In such
cases, the maximum number of such substituents is three.
That is to say that each of the above definitions is constrained by a limitation that, for example, substituted aryl
groups are limited to -substituted aryl-(substituted aryl)substituted aryl.
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Compounds of the present invention are mono quaternary
ammonium salts corresponding to Formula (I):

methyl unsaturated azetidine, methyl unsaturated N-methyl
azetidine, methyl piperidine, methyl N-methyl piperidine,
methyl unsaturated piperidine, methyl unsaturated N-methyl
piperidine, methyl azepane, methyl N-methyl azepane,
methyl unsaturated azepane, methyl unsaturated N-methyl
azepane, methyl azocane, methyl N-methyl azocane, methyl
unsaturated azocane, methyl unsaturated N-methyl azocane,
methyl-1-aza-bicyclo [3 .2 .1] octane, methy1-1-aza -bicyclo
[2.2.1]heptane, 8-methyl-8-aza-bicyclo[3.2.1]octane, and
methyl-1-aza-tricyclo[3.3.1.1 3 .7]decane.
As another example, when R 1 and R 2 , or R 2 and R3
together with the carbons to which they are attached, independently form a three to eight-membered ring, that ring
may be a heterocycle containing up to three hetero atoms
(for example nitrogen, oxygen or sulfur) in the ring, and
further may be substituted with one or more substituents. For
example, possible rings include benzene, pyridine, pyran,
indene, isoindene, benzofuran, isobenzofuran, benzo[b ]thiophene, benzo[c]thiophene, indole, indolenine, isoindole,
cyclopental[b ]pyridine, pyrano[3,4-b ]pyrrole, indazole,
indoxazine, benzoxazole, anthranil naphthalene, tetralin,
decalin, chromene, coumarin, chroman-4-one, isocoumarin,
isochromen-3-one, quinoline, isoquinoline, ciunoline, quinazoline, naphthyridine, pyrido[3,4-b ]-pyridine, pyridol[3,
2-b ]pyridine, pyrido[ 4,3-b ]-pyridine, benzoxazine, anthracene, phenanthrene, phenalene, fluorene, carazole, xanthene,
acnidine, octahydro- [!]pyridine, 1-methy loctahydro- [1]
pyridine, octahydroindole, 1-methyloctahydro-indole, octahydro-cyclopenta[b ]pyrrole, 1-methyloctahydro-cyclopenta
[b ]pyrrole,
decahydroquinoline,
or
1-methyldecahydroquinoline.
As a further example, heterocycles formed by A 1 , A 2 , A 3 ,
A 4 , and As in combination with R 1 , R 2 , R3 , R4 , and Rs
include pyridine, quinoline, 5,6,7,8-tetrahydroquinoline,
isoquinoline, tetrahydroisoquinoline, pyrazine, pyrimidine,
pyridazine, and triazine, as well as substituted forms thereof.
Z 1 for example includes alkyl (for example butyl or
pentyl), cis-alkenyl; trans-alkenyl; substituted cis-alkenyl;
substituted trans-alkenyl; alkynyl (for example but-3-ynyl or
pent-4-ynyl).
Z 2 for example includes cis-alkenyl, trans-alkenyl, substituted cis-alkenyl, and substituted trans-alkenyl.
x- for example includes Cl-, Br-, I-, N0 2 -, HS04 -,
SO4 -, HPO4 -, PO4 2 -, ethanesulfonate, trifluoromethane sulfate, p-toluenesulfonate, benzenesulfonate, salicylate, proprionate, ascorbate, aspartate, fumarate, galactarate,
maleate, citrate, glutamate, glycolate, lactate, malate,
maleate, tartrate, oxalate, succinate, or similar pharmaceutically acceptable organic acid addition salts, including the
pharmaceutically acceptable salts listed in the Journal of
Pharmaceutical Sciences volume 66, page 2, 1977, which
are hereby incorporated by reference. The above salt forms
may be in some cases hydrates or solvates with alcohols and
other solvents.
In a compound of Formula (I), preferably A 1 , A 2 , A 3 , A 4 ,
and As are carbon.
In a compound of Formula (I), preferably R 1 is hydrogen,
alkyl, or forms a six membered ring with A I, A 2 and R 2 and
with R 1 and R 2 providing four carbon atoms. More preferably, R 1 is selected from hydrogen, methyl, forms a six
membered ring with A 1 , A 2 and R 2 and with R 1 and R 2
providing four unsaturated carbon atoms, or forms a phenyl
group with A I, A 2 and R 2 .
In a compound of Formula (I), preferably R 2 is hydrogen,
alkyl, aryl, 3-hydroxypropyl, 1-methyl-2-pyrrolidinyl, halo,
forms a six membered ring with A 1 , A 2 and R 1 and with R 1
and R 2 providing four carbon atoms, or forms a six mem-

(I)

5
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A\ A 2 , A 3 , A 4 , and As are independently selected from
nitrogen or carbon, provided that when nitrogen is present,
the nitrogen does not have an R substituent attached.
R 1 , R 2 , R3 , R4 , and Rs are each independently selected
from the group consisting of hydrogen, alkyl, substituted
alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted
alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl,
heterocycle, substituted heterocycle, halo, cyano, and nitro,
orR 1 and R 2 orR2 and R3 together with the carbons to which
they are attached independently form a three to eightmember cycloalkane, substituted cycloalkane, cycloalkene,
substituted cycloalkene, aryl, substituted aryl, heterocycle
with one to three hetero atoms in the ring, or substituted
heterocycle with one to three hetero atoms in the ring.
Z 1 is absent or is selected from the group consisting of
alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl,
alkenyl, substituted alkenyl, alkynyl, substituted alkynyl,
phenylene, substituted phenylene, alkoxy, and substituted
alkoxy.
Z2 is selected from the group consisting of alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, arylene, substituted arylene, heterocycle, substituted heterocycle,
alkoxy, and substituted alkoxy.
Z3 is selected from is selected from hydrogen, alkyl,
substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl,
substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heterocycle, and substituted heterocycle.
x- is an inorganic or organic anion.
For example, R\ R 2 , R3 , R4 , and Rs include hydrogen,
methyl, ethyl, propyl, butyl, trifluoromethyl, pyrrolidine,
N-alkyl pyrrolidine (for example where the alkyl chain is
methyl, ethyl or propyl), unsaturated pyrrolidine, unsaturated N-alkyl pyrrolidine (for example where the alkyl chain
is methyl, ethyl or propyl), aziridine, N-methyl aziridine,
azetidine, N-methyl azetidine, unsaturated azetidine, unsaturated N-methyl azetidine, piperidine, N-methyl piperidine,
unsaturated piperidine, unsaturated N-methyl piperidine,
azepane, N-methyl azepane, unsaturated azepane, unsaturated N-methyl azepane, azocane, N-methyl azocane,
unsaturated azocane, unsaturated N-methyl azocane, l-azabicyclo[3.2.1]octane,
l-aza-bicyclo[2.2.1]heptane,
8-methyl-8-aza-bicyclo[3.2.1]octane,
1-aza-tricyclo
[3.3.1.1 3 .7]decane, methyl cycloalkyl, methyl substituted
cycloalkyl, methylpyrrolidine, methyl N-alkyl pyrrolidine
(for example where the alkyl chain is methyl, ethyl or
propyl), methyl unsaturated pyrrolidine, methyl unsaturated
N-alkyl pyrrolidine (for example where the alkyl chain is
methyl, ethyl or propyl), methyl aziridine, methyl N-methyl
aziridine, methyl azetidine, methyl N-methyl azetidine,
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bered ring withA2 , A 3 and R3 and with R 2 and R3 providing
four carbon atoms. More preferably, R 2 is hydrogen, methyl,
ethyl, butyl, phenyl, 3-hydroxypropyl, 1-methyl-2-pyrrolidinyl, bromo, forms a six membered ring with A\ A 2 and R 1
and with R 1 and R 2 providing four unsaturated carbon
atoms, forms a phenyl group with A 1 , A 2 and R 1 , forms a six
membered ring with A 2 , A 3 and R3 and with R 2 and R3
providing four unsaturated carbon atoms, or forms a phenyl
group with A 2 , A 3 and R3 .
In a compound of Formula (I), preferably R3 is hydrogen,
alkyl, or forms a six membered ring withA2 , A 3 and R 2 and
with R 2 and R3 providing four carbon atoms. More preferably, R3 is hydrogen, methyl, forms a six membered ring
with A 2 , A 3 and R 2 and with R 2 and R3 providing four
unsaturated carbon atoms, or forms a phenyl group withA2 ,
A 3 and R 2 .
In a compound of Formula (I), preferably R4 is hydrogen
or alkyl. More preferably, R4 is hydrogen or methyl.
In a compound of Formula (I), preferably R5 is hydrogen.
In a compound of Formula (I), preferably Z 1 is absent, or
is alkyl, alkynyl, or alkoxy. More preferably, Z 1 is absent,
butyl, but-3-ynyl, pentyl, pent-4-ynyl or 2-ethoxy.
In a compound of Formula (I), preferably Z 2 is alkyl,
arylenyl or alkoxy. More preferably, Z2 is hexyl, octyl,
dodecyl, tridecyl, para-phenylene, or 2-ethoxy.
In a compound of Formula (I), preferably Z3 is alkyl,
alkynyl, aryl or heterocyclic. More preferably Z3 is propyl,
butyl, but-1-ynyl, hex-1-ynyl, phenyl, or 3-pyridinyl.
In a compound of Formula (I), preferably X is a halogen.
More preferably, X is chloride, bromide or iodide.
In one embodiment, the compound of Formula (I) is
defined wherein A\ A 2 , A 3 , A 4 , andA5 are carbon; wherein
R 1 is hydrogen, methyl, forms a six membered ring with A 1 ,
A 2 and R2 and with R 1 and R 2 providing four unsaturated
carbon atoms, or forms a phenyl group with A\ A 2 and R 2 ;
wherein R 2 is hydrogen, methyl, ethyl, butyl, phenyl, 3-hydroxypropyl, 1-methyl-2-pyrrolidinyl, bromo, forms a six
membered ring with A 1 , A 2 and R 1 and with R 1 and R 2
providing four unsaturated carbon atoms, forms a phenyl
group with A 1 , A 2 and R 1 , forms a six membered ring with
A 2 , A 3 and R3 and with R 2 and R3 providing four unsaturated
carbon atoms, or forms a phenyl group withA2 , A 3 and R3 ;

wherein R3 is hydrogen, methyl, forms a six membered ring
with A 2 , A 3 and R 2 and with R 2 and R3 providing four
unsaturated carbon atoms, or forms a phenyl group withA2 ,
A 3 and R 2 ; wherein R4 is hydrogen or methyl; wherein R5 is
hydrogen; wherein Z 1 is absent, butyl, but-3-ynyl, pentyl,
pent-4-ynyl or 2-ethoxy; wherein Z 2 is hexyl, octyl, dodecyl,
tridecyl, para-phenylene, or 2-ethoxy; wherein Z3 is propyl,
butyl, but-1-ynyl, hex-1-ynyl, phenyl, or 3-pyridinyl; and
wherein X is chloride, bromide or iodide.
In another embodiment, the compound of Formula (I) is
defined wherein A\ A 2 , A 3 , A 4 , andA5 are carbon; wherein
R 1 is hydrogen, methyl, forms a six membered ring withA 1 ,
A 2 and R 2 and with R 1 and R2 providing four unsaturated
carbon atoms, or forms a phenyl group withA 1 , A 2 and R 2 ;
wherein R 2 is hydrogen, methyl, ethyl, 3-hydroxypropyl,
1-methyl-2-pyrrolidinyl, bromo, forms a six membered ring
with A\ A 2 and R 1 and with R 1 and R 2 providing four
unsaturated carbon atoms, forms a phenyl group with A 1 , A 2
and R\ forms a six membered ring withA2 , A 3 and R3 and
with R 2 and R3 providing four unsaturated carbon atoms, or
forms a phenyl group with A 2 , A 3 and R3 ; wherein R3 is
hydrogen, methyl, forms a six membered ring with A 2 , A 3
and R 2 and with R 2 and R3 providing four unsaturated
carbon atoms, or forms a phenyl group withA2 , A 3 and R 2 ;
wherein R4 is hydrogen or methyl; wherein R5 is hydrogen;
wherein Z 1 is absent, butyl, but-3-ynyl, pent-4-ynyl or
2-ethoxy; wherein Z 2 is hexyl, octyl, dodecyl, tridecyl,
para-phenylene, or 2-ethoxy; wherein Z3 is propyl, butyl,
but-1-ynyl, hex-1-ynyl, phenyl, or 3-pyridinyl; and wherein
X is chloride, bromide or iodide.
In another embodiment, the compound of Formula (I) is
defined wherein A\ A 2 , A 3 , A 4 , andA5 are carbon; wherein
R 1 is hydrogen, methyl, or forms a phenyl group withA 1 , A 2
and R 2 ; wherein R 2 is hydrogen, methyl, butyl, phenyl,
1-methyl-2-pyrrolidinyl, forms a phenyl group with A\ A 2
and R\ or forms a phenyl group withA2 ,A3 andR3 ; wherein
R3 is hydrogen, methyl, or forms a phenyl group withA2 , A 3
and R 2 ; wherein R4 is hydrogen or methyl; wherein R5 is
hydrogen; wherein Z 1 is pentyl or pent-4-ynyl; wherein Z 2
is para-phenylene; wherein Z3 is phenyl; and wherein X is
bromide.
Exemplary compounds for this application are presented
in Table 1.
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TABLE 1

ID#
GZ-565A
GZ-565B
GZ-565C
GZ-566A
GZ-566B
GZ-566C
GZ-567A
GZ-567B
GZ-567C
GZ-568A

Rl

R2

R3

R4

zl

z2

z3

X

H
Me
H
H
H
Me
phenyl with R2
H
H
H

Me
H
H
Me
Me
H
phenyl with R 1
phenyl with R 3
!-methyl-2-pyrrolidinyl
butyl

H
H
Me
H
Me
Me
H
phenyl with R2
H
H

H
H
H
Me
H
H
H
H
H
H

but-3-ynyl
but-3-ynyl
but-3-ynyl
but-3-ynyl
but-3-ynyl
but-3-ynyl
but-3-ynyl
but-3-ynyl
but-3-ynyl
but-3-ynyl

p-phenyl
p-phenyl
p-phenyl
p-phenyl
p-phenyl
p-phenyl
p-phenyl
p-phenyl
p-phenyl
p-phenyl

phenyl
phenyl
phenyl
phenyl
phenyl
phenyl
phenyl
phenyl
phenyl
phenyl

bromide
bromide
bromide
bromide
bromide
bromide
bromide
bromide
bromide
bromide
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TABLE !-continued

ID#

GZ-568B
GZ-568C
GZ-573A
GZ-573B
GZ-573C
GZ-574A
GZ-574B
GZ-574C
GZ-575A
GZ-575B
GZ-575C
GZ-576A
GZ-576B
ZZ-1-101
ZZ-1-104
ZZ-1-107
ZZ-1-137A
ZZ-1-137C
ZZ-1-137D
ZZ-1-137F

ZZ-1-26
ZZ-1-29
ZZ-1-40A
ZZ-1-40B
ZZ-1-40C
ZZ-1-40D
ZZ-1-40E
ZZ-1-40F
ZZ-1-40G

ZZ-1-40H

ZZ-1-401
ZZ-1-40J
ZZ-1-47
ZZ-1-48
ZZ-1-49
ZZ-1-50
ZZ-1-70
ZZ-1-71
ZZ-1-71A
ZZ-1-71B
ZZ-1-71C
ZZ-1-71D
ZZ-1-71E
ZZ-1-71F
ZZ-1-71H

H
H
H

phenyl

Me

H
H

H
H
H

Me
phenyl with R2
H
H
H
H
H

Me

Me
Me
H
1

phenyl with R
phenyl with R3
!-methyl-2-pyrrolidinyl
butyl
H

3-hydroxypropyl

Me
Me

H
H

H
H
H
H

Me
Me
Me
ring with R3 , R2 &
3
R provide 4

H
H
H
H
H
H

Me
Me
ring with R 2 , R 1 &
2
R provide 4

H

Me

Me
Me

H
H
H
H
H
H
H
H
H
H
H

H

phenyl with R2
H
H
H
H
H

Me
H
H

Me
ring with R2 , R2 &
3
R provide 4

nnsaturated carbons
H

unsaturated carbons

!-methyl-2-pyrrolidinyl
Me

H
H

H

Me
Me

Me
Me

Me

H
H

H
H

Me
1

ring with Rl, R &
R 2 provide 4

unsaturated carbons
H

nnsaturated carbons
ring with R3 , R2 &
R 3 provide 4
nnsaturated carbons

H
H
H
H

!-methyl-2-pyrrolidinyl
hydroxypropyl
Me

Me
Me

Me

H
H
H
H
H

H
H
H
H

H

H
H
H

H

ring with R2 , R2 &
R3 provide 4
unsaturated carbons
H
H
H

ZZ-1-72
ZZ-1-73
ZZ-1-74

H
H
H

ZZ-1-76
ZZ-1-77
ZZ-1-77A
ZZ-1-77B
ZZ-1-77C

H
H
H
H
H

Me
Me
ring with R3 , R2 &
R 3 provide 4
nnsaturated carbons
Et
hydroxypropyl
Me

2-ethoxy

hexyl

chloride

hexyl
hexyl
phenyl
phenyl
phenyl
phenyl
butyl
butyl
propyl
propyl
propyl
propyl
propyl
propyl
propyl

chloride
chloride
bromide
bromide
bromide
bromide
bromide
bromide
bromide
bromide
bromide
bromide
bromide
bromide
bromide

butyl
butyl
butyl

bromide
bromide
bromide

Me
H
H

prop-2-ynyl p-phenyl
prop-2-ynyl p-phenyl
prop-2-ynyl p-phenyl

H
H

H

methoxy

H
H

H
H

H
ring with R3 , R2 &
3
R provide 4
nnsaturated carbons

H

Me

Me

Me

unsaturated carbons
H

Me
ring with R2 , R2 &
R3 provide 4
unsaturated carbons
H
H
H

H

[[H]]Me

Br

H

bromide
bromide
bromide
bromide
bromide
bromide
bromide
bromide
bromide
bromide
bromide
bromide
bromide
bromide
bromide
bromide
bromide
bromide
bromide
bromide

H
H
H

Me

H

H

Me

phenyl
phenyl
phenyl
phenyl
phenyl
phenyl
phenyl
phenyl
phenyl
phenyl
phenyl
phenyl
phenyl
butyl
butyl
butyl
3-pyridinyl
3-pyridinyl
3-pyridinyl
3-pyridinyl

methoxy
methoxy
methoxy
methoxy
methoxy
methoxy
methoxy

Me
ring with R2 , R2 &
3
R provide 4

H

Me

X

hexyl hex-1-ynyl iodide
hexyl hex-1-ynyl iodide
2-ethoxy
hexyl
chloride
2-ethoxy
hexyl
chloride
2-ethoxy
hexyl
chloride
2-ethoxy
hexyl
chloride
2-ethoxy
hexyl
chloride
2-ethoxy
hexyl
chloride
2-ethoxy
hexyl
chloride

H
H
H
H
H

Me
Me

Me

H

Me

H
H

2-ethoxy
2-thoxy
heptyl
heptyl
heptyl
heptyl
prop-2-ynyl p-phenyl
prop-2-ynyl p-phenyl
but-3-ynyl p-phenyl
but-3-ynyl p-phenyl
but-3-ynyl p-phenyl
but-3-ynyl p-phenyl
but-3-ynyl p-phenyl
but-3-ynyl p-phenyl
but-3-ynyl p-phenyl

Me

Me
Me

Me

p-phenyl
p-phenyl
p-phenyl
p-phenyl
p-phenyl
p-phenyl
p-phenyl
p-phenyl
p-phenyl
p-phenyl
p-phenyl
p-phenyl
p-phenyl
p-phenyl
p-phenyl
p-phenyl
dodecyl
dodecyl
dodecyl
dodecyl

H
H
H
H
H
H
H
H
H
H
H
H

H
H
H
H
H
H

but-3-ynyl
but-3-ynyl
butyl
butyl
butyl
butyl
butyl
butyl
butyl
butyl
butyl
butyl
butyl
propyl
propyl
propyl

z3

H
H
H
H
H

methoxy
methoxy

prop-2-ynyl p-phenyl
bromide
butyl
prop-2-ynyl p-phenyl
bromide
butyl
undecyl 3-pyridinyl bromide
undecyl 3-pyridinyl bromide
undecyl 3-pyridinyl bromide
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TABLE !-continued

ID#

Rl

ZZ-1-77D
ZZ-1-77E
ZZ-1-77F
ZZ-1-94
ZZ-1-95
ZZ-1-96
ZZ-1-97
ZZ-1-98

H
H
H
H
H
H
H
H

ZZU-1
ZZU-2
ZZU-3
ZZU-4
ZZU-5
ZZU-6
ZZU-7
ZZU-8

Me
H
Me
H
H
Me
H
H

R2

R3

R4

Me
Me
H
Me
H
Me
!-methyl-2-pyrrolidinyl
H
H
Me
H
H
H
Me
H
Me
H
Me
Me
Me
H
3
2
2
2
ring with R , R &
ring with R , R &
H
3
3
R provide 4
R provide 4
nnsaturated carbons
unsaturated carbons
H
H
H
Me
H
H
H
Me
H
Me
H
Me
Me
Me
H
H
H
H
Me
H
H
H
Me
H

zl

propyl
propyl
propyl
propyl
propyl

z2

z3

X

undecyl 3-pyridinyl bromide
undecyl 3-pyridinyl bromide
undecyl 3-pyridinyl bromide
p-phenyl
butyl
bromide
p-phenyl
butyl
bromide
p-phenyl
butyl
bromide
p-phenyl
butyl
bromide
p-phenyl
butyl
bromide

hexyl
hexyl
hexyl
hexyl
hexyl
octyl
octyl
octyl

hex-1-ynyl iodide
hex-1-ynyl iodide
hex-1-ynyl iodide
hex-1-ynyl iodide
hex-1-ynyl iodide
but-1-ynyl bromide
but-1-ynyl bromide
but-1-ynyl bromide

Exemplary compounds of the present invention include:
methyl-pyridinium bromide; 1-[5-(1,1'-biphenyl-4-yl)-pent2-methyl-1-(8-phenyl-octyl)-pyridinium
bromide;
4-ynyl]-3-methyl-pyridinium bromide; 1-[5-(1 ,1 '-biphenyl3-methyl-1-(8-phenyl-octyl)-pyridinium bromide; 2,4-dim- 35 4-yl)-pent-4-ynyl]-4-methyl-pyridinium bromide; 1-[5-(1,
1'-biphenyl-4-y I)-pent -4-yny1]-2,4-dimethy1-pyridinium
ethyl-1-(8-phenyl-octyl)-pyridinium bromide; 4-methyl-1bromide;
1-[5-(1 ,1 '-biphenyl-4-yl)-pent-4-ynyl]-3,4-dim(8-phenyl-octyl)-pyridinium bromide; 1-dodec-7 -ynyl-2methyl-pyridinium
iodide;
1-dodec-7-ynyl-3-methylethyl-pyridinium bromide; 1-[5-(1,1'-biphenyl-4-yl)-pent-4pyridinium iodide; 1-dodec-7-ynyl-4-methyl-pyridinium
ynyl]-3,5-dimethyl-pyridinium bromide; 1-[5-(1, 1'-bipheiodide; 1-dodec-7 -ynyl-2,4-dimethyl-pyridinium iodide; 40 nyl-4-yl)-pent-4-ynyl]-quinolinium bromide; 2-[5-(1,1 '1-dodec-7 -ynyl-3,5-dimethyl-pyridinium iodide; 1-dodec-7biphenyl-4-yl)-pent-4-ynyl]-isoquinolinium bromide; 1-[5ynyl-3,4-dimethyl-pyridinium iodide; 1-dodec-9-ynyl-2(1, 1'-biphenyl-4-yl)-pent-4-ynyl]-3-butyl-pyridinium
bromide; 1-[5-(1,1'-biphenyl-4-yl)-pent-4-ynyl]-3-phenylmethyl-pyridinium bromide; 1-dodec-9-ynyl-3-methyl-pyridinium bromide;
1-dodec-9-ynyl-4-methyl-pyridinium
pyridinium bromide; 1-[5-(1 ,1 '-biphenyl-4-yl)-pent-4-ynyl]bromide; 1-[ 4-(4-butyl-phenyl)-butyl]-2-methyl-pyridinium 45 1-pyridinium bromide; 1-[5-(1,1 '-biphenyl-4-yl)-pentyl]-2bromide; 1-[ 4-(4-butyl-phenyl)-butyl]-3-methyl-pyridinium
methyl-pyridinium bromide; 1-[5-(1,1'-biphenyl-4-yl)bromide; 1-[ 4-(4-butyl-phenyl)-butyl]-4-methyl-pyridinium
pentyl]-3-methyl-pyridinium bromide; 1-[5-(1 ,1 '-biphenylbromide; 2-[ 4-( 4-butyl-phenyl)-butyl]-5,6, 7 ,8-tetrahydro4-yl)-pentyl]-4-methyl-pyridinium bromide; 1-[5-(1,1 'isoquinolinium bromide; 1-[ 4-(4-butyl-phenyl)-butyl]-3-(3biphenyl-4-yl)-pentyl]-2,4-dimethyl-pyridinium bromide;
hydroxy-propyl)-pyridinium bromide; 1-[ 4-(4-butyl-phe- so 1-[ 5-(1, 1'-biphenyl-4-yl)-pentyl]-3,4-dimethyl-pyridinium
bromide;
1-[ 5-(1, 1'-biphenyl-4-yl)-pentyl]-3,5-dimethylnyl)-butyl]-2,4-dimethyl-pyridinium bromide;
1-[ 4-(4butyl-phenyl)-butyl]-3,4-dimethyl-pyridinium
bromide;
pyridinium bromide; 1-[5-(1 ,1 '-biphenyl-4-yl)-pentyl]-qui1-[ 4-(4-butyl-phenyl)-butyl]-3,5-dimethyl-pyridinium bronolinium bromide; 2-[5-(1 ,1 '-biphenyl-4-yl)-pentyl]-isoquimide;
1-[4-( 4-butyl-phenyl)-but-3-ynyl]-3-methyl-pyrinolinium bromide; 1-[5-(1,1 '-biphenyl-4-yl)-pentyl]-3dinium
bromide;
1-[4-(4-butyl-phenyl)-but-3-ynyl]-4- 55 butyl-pyridinium
bromide;
1-[5-(1,1'-biphenyl-4-yl)methyl-pyridinium bromide; 1-[4-( 4-butyl-phenyl)-but-3pentyl]-pyridinium bromide; 1-dodec-7 -ynyl-3-(1-methylynyl]-3-ethyl-pyridinium bromide; 2-[ 4-(4-butyl-phenyl)2-pyrrolidinyl)-pyridinium iodide; 3-methyl-1-[4-( 4-propylbut-3-ynyl]-5,6,7,8-tetrahydro-isoquinolinium
bromide;
phenyl)-pent-4-ynyl]-pyridinium bromide; 2-methyl-1-[ 41-[ 4-(4-butyl-phenyl)-but-3-ynyl]-3,4-dimethyl-pyridinium
(4-propyl-phenyl)-pent-4-ynyl]-pyridinium
bromide;
bromide; 1-[ 4-(4-butyl-phenyl)-but-3-ynyl]-3,5-dimethyl- 60 4-methyl-1-[ 4-( 4-propyl-phenyl)-pent-4-ynyl]-pyridinium
pyridinium bromide; 1-[4-(4-butyl-phenyl)-but-3-ynyl]-3bromide;
3,4-dimethyl-1-[4-(4-propyl-phenyl)-pent-4(3-hydroxy-propyl)-pyridinium bromide; 3-methyl-1-[13ynyl]-pyridinium bromide; 3,5-dimethyl-1-[4-( 4-propyl(3-pyridinyl)-tridecyl]-pyridinium bromide; 3,4-dimethyl-1phenyl)-pent-4-ynyl]-pyridinium bromide; 2,4-dimethyl-1[13-(3-pyridinyl)-tridecyl]-pyridinium
bromide;
3,5[4-(4-propyl-phenyl)-pent-4-ynyl]-pyridinium
bromide;
dimethyl-1-[13-(3-pyridinyl)-tridecyl]-pyridinium bromide; 65 2-[ 4-(4-propyl-phenyl)-pent-4-ynyl]-5,6, 7 ,8-tetrahydro-isoquinolinium bromide; 1-[5-(1, 1'-biphenyl-4-yl)-pent-42-[ 13 -(3 -pyridiny1)-tridecyl]-5, 6, 7, 8-tetrahydro-isoquinolinium bromide; 1-[5-(1 ,1 '-biphenyl-4-yl)-pent-4-ynyl]-2ynyl]-3-(1-methyl-2-pyrrolidinyl)-pyridinium
bromide;
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1-[ 5-(1, 1'-biphenyl-4-yl)-pentyl]-3-(1-methyl-2-pyrrolidi-

nyl)-pyridinium bromide; 1-[2-(2-hexoxy-ethoxy)-ethyl]-3methyl-pyridinium chloride; 1-[2-(2-hexoxy-ethoxy)-ethyl]4-methyl-pyridinium chloride; 1-[2-(2-hexoxy-ethoxy)ethyl]-3,4-dimethyl-pyridinium chloride; 1-[2-(2-hexoxyethoxy )-ethyl]-3,5-dimethyl-pyridinium chloride; 1-[2-(2hexoxy-ethoxy )-ethyl]-2-methyl-pyridinium chloride; 1-[2(2-hexoxy-ethoxy)-ethyl]-2,4-dimethyl-pyridinium
chloride; 1-[2-(2-hexoxy-ethoxy)-ethyl]-5,6, 7 ,8-tetrahydroquinolinium chloride; 2-[2-(2-hexoxy-ethoxy)-ethyl]-5,6,7,
8-tetrahydro-isoquinolinium chloride;
1-[2-(2-hexoxyethoxy)-ethyl]-3-methyl-pyridinium
chloride;
1-[2-(2chloride;
hexoxy-ethoxy )-ethy1]-3 -methy1-pyridinium
3-methyl-1-[12-(3-pyridinyl)-dodecyl]-pyridinium
bromide;
4-methyl-1-[12-(3-pyridinyl)-dodecyl]-pyridinium
bromide; 3-bromo-1-[12-(3-pyridinyl)-dodecyl]-pyridinium
bromide; 3,4-dimethyl-1-[12-(3-pyridinyl)-dodecyl]-pyridinium bromide; 3,5-dimethyl-1-[12-(3-pyridinyl)-dodecyl]-pyridinium bromide; and 3-(1-methyl-2-pyrrolidinyl)1-[ 12-(3-pyridinyl)-dodecyl]-pyridinium bromide.
The compounds of the present invention may contain one
or more stereocenters. The invention includes all possible
diastereomers and all enantiomeric forms as well as racemic
mixtures. The compounds can be separated into substantially optically pure compounds.
The compounds of the invention are nicotinic acetylcholine receptor agents. Thus, they may augment or inhibit
3
3
[ H]nicotine binding, [ H]MLA binding, evoke or inhibit
neurotransmitter release, and/or evoke or inhibit the flux of
ions through the nicotinic receptor.
In one embodiment, the present invention relates to a
method for selectively modulating the function of a nicotinic
acetylcholine receptor comprising administering to a mammalian subject in need thereof a therapeutically effective
amount of a compound of Formula (I). In such a method, the
compound of Formula (I) may selectively bind to one or
more subtypes of nicotinic acetylcholine receptor. The compound of Formula (I) may act as an agonist or partial agonist
of nicotinic acetylcholine receptor function. Hence the compound of Formula (I) may increase or prolong the release of
a neurotransmitter from a central nervous system tissue. The
neurotransmitter affected may include dopamine, norepinephrine, serotonin, gma-aminobutyric acid, or glutamate. Alternatively, the compound of Formula (I) may act as
an antagonist of nicotinic acetylcholine receptor function.
Hence the compound of Formula (I) may decrease the extent
or duration of the release of a neurotransmitter from a central
nervous system tissue. The neurotransmitter affected may
include dopamine, norepinephrine, serotonin, gamma-aminobutyric acid, or glutamate.
In another embodiment, the present invention is directed
to a method for preventing and/or treating a central nervous
system associated disorder comprising administering to a
mammalian subject in need thereof a therapeutically effective amount of a compound of Formula (I). In such a
method, the compound of Formula (I) may selectively bind
to one or more subtypes of nicotinic acetylcholine receptor.
The compound of Formula (I) may act as an agonist or
partial agonist of nicotinic acetylcholine receptor function.
Hence the compound of Formula (I) may increase or prolong
the release of a neurotransmitter from a central nervous
system tissue. The neurotransmitter affected may include
dopamine, norepinephrine, serotonin, gamma-aminobutyric
acid, or glutamate. Alternatively, the compound of Formula
(I) may act as an antagonist of nicotinic acetylcholine
receptor function. Hence the compound of Formula (I) may
decrease the extent or duration of the release of a neurotrans-
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mitter from a central nervous system tissue. The neurotransmitter affected may include dopamine, norepinephrine, serotonin, gamma-aminobutyric acid, or glutamate.
Central nervous system disorders which may be treated
according to the method of the present invention include
Alzheimer's disease, dementia, cognitive dysfunctions (including disorders of attention, focus and concentration),
attention deficit disorders, affective disorders, extrapyramidal motor function disorders, Parkinson's disease, progressive supramolecular palsy, Huntington's disease, Gilles de Ia
Tourette syndrome, tardive dyskinesia, neuroendocrine disorders, dysregulation of food intake, disorders of nociception, pain, mood and emotional disorders, depression, panic
anxiety, psychosis, schizophrenia, or epilepsy.
In yet another embodiment, the present invention is
directed to a method for preventing and/or treating substance
use and/or abuse comprising administering to a mmalian
subject in need thereof a therapeutically effective amount of
a compound of Formula (I). In such a method, the compound
of Formula (I) may selectively bind to one or more subtypes
of nicotinic acetylcholine receptor. The compound of Formula (I) may act as an agonist or partial agonist of nicotinic
acetylcholine receptor function. Hence the compound of
Formula (I) may increase or prolong the release of a neurotransmitter from a central nervous system tissue. The
neurotransmitter affected may include dopamine, norepinephrine, serotonin, gamma-aminobutyric acid, or glutamate. Alternatively, the compound of Formula (I) may act as
an antagonist of nicotinic acetylcholine receptor function.
Hence the compound of Formula (I) may decrease the extent
or duration of the release of a neurotransmitter from a central
nervous system tissue. The neurotransmitter affected may
include dopamine, norepinephrine, serotonin, gamma-aminobutyric acid, or glutamate.
The conditions of substance use and/or abuse treated
according to the method of the present invention include
nicotine abuse (including use in smoking cessation therapy),
nicotine intoxication, amphetamine abuse, methamphetamine abuse, cocaine abuse, or alcohol abuse.
In another embodiment, the present invention is directed
to a method for preventing and/or treating gastrointestinal
tract disorders comprising administering to a mmalian
subject in need thereof a therapeutically effective amount of
a compound of Formula (I). In such a method, the compound
of Formula (I) may selectively bind to one or more subtypes
of nicotinic acetylcholine receptor. The compound of Formula (I) may act as an agonist or partial agonist of nicotinic
acetylcholine receptor function. Hence the compound of
Formula (I) may increase or prolong the release of a neurotransmitter from a central nervous system tissue. The
neurotransmitter affected may include dopamine, norepinephrine, serotonin, gamma-aminobutyric acid, or glutamate. Alternatively, the compound of Formula (I) may act as
an antagonist of nicotinic acetylcholine receptor function.
Hence the compound of Formula (I) may decrease the extent
or duration of the release of a neurotransmitter from a central
nervous system tissue. The neurotransmitter affected may
include dopamine, norepinephrine, serotonin, gamma-aminobutyric acid, or glutamate.
Gastrointestinal disorders which may be treated according
to the method of the present invention include irritable
bowel syndrome, colitis, diarrhea, constipation, gastric acid
secretion or ulcers.
The compounds of the present invention can be delivered
directly or in pharmaceutical compositions along with suitable carriers or excipients, as is well known in the art. For
example, a pharmaceutical composition of the invention
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may include a conventional additive, such as a stabilizer,
buffer, salt, preservative, filler, flavor enhancer and the like,
as known to those skilled in the art. Exemplary buffers
include phosphates, carbonates, citrates and the like. Exemplary preservatives include EDTA, EGTA, BHA, BHT and
the like.
An effective amount of such agents can readily be determined by routine experimentation, as can the most effective
and convenient route of administration and the most appropriate formulation. Various formulations and drug delivery
systems are available in the art. See, e.g., Gennaro, A. R., ed.
(1995) Remington's Pharmaceutical Sciences.
Suitable routes of administration may, for example,
include oral, rectal, transmucosal, nasal, or intestinal administration and parenteral delivery, including intramuscular,
subcutaneous, intramedullary injections, as well as intrathecal, direct intraventricular, intravenous, intraperitoneal,
intranasal, or intraocular injections. The agent or composition thereof may be administered in a local rather than a
systemic manner. For example, a suitable agent can be
delivered via injection or in a targeted drug delivery system,
such as a depot or sustained release formulation.
The pharmaceutical compositions of the present invention
may be manufactured by any of the methods well-known in
the art, such as by conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifYing, encapsulating, entrapping, or lyophilizing processes. As noted above,
the compositions of the present invention can include one or
more physiologically acceptable carriers such as excipients
and auxiliaries that facilitate processing of active molecules
into preparations for pharmaceutical use.
Proper formulation is dependent upon the route of administration chosen. For injection, for example, the composition
may be formulated in aqueous solutions, preferably in
physiologically compatible buffers such as Hanks' solution,
Ringer's solution, or physiological saline buffer. For transmucosal or nasal administration, penetrants appropriate to
the barrier to be permeated are used in the formulation. Such
penetrants are generally known in the art. In a preferred
embodiment of the present invention, the present compounds are prepared in a formulation intended for oral
administration. For oral administration, the compounds can
be formulated readily by combining the active compounds
with pharmaceutically acceptable carriers well known in the
art. Such carriers enable the compounds of the invention to
be formulated as tablets, pills, dragees, capsules, liquids,
gels, syrups, slurries, suspensions and the like, for oral
ingestion by a subject. The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases
such as cocoa butter or other glycerides.
Pharmaceutical preparations for oral use can be obtained
as solid excipients, optionally grinding a resulting mixture,
and processing the mixture of granules, after adding suitable
auxiliaries, if desired, to obtain tablets or dragee cores.
Suitable excipients are, in particular, fillers such as sugars,
including lactose, sucrose, mannitol, or sorbitol; cellulose
preparations such as, for example, maize starch, wheat
starch, rice starch, potato starch, gelatin, gum tragacanth,
methyl cellulose, hydroxypropylmethyl-cellulose, sodium
carboxymethylcellulose,
and/or
polyvinylpyrrolidone
(PVP). If desired, disintegrating agents may be added, such
as the cross-linked polyvinyl pyrrolidone, agar, or alginic
acid or a salt thereof such as sodium alginate. Also, wetting
agents such as sodium dodecyl sulfate may be included.
Dragee cores are provided with suitable coatings. For this
purpose, concentrated sugar solutions may be used, which

may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium
dioxide, lacquer solutions, and suitable organic solvents or
solvent mixtures. Dyestuffs or pigments may be added to the
tablets or dragee coatings for identification or to characterize
different combinations of active compound doses.
Pharmaceutical preparations for oral administration
include push-fit capsules made of gelatin, as well as soft,
sealed capsules made of gelatin and a plasticizer, such as
glycerol or sorbitol. The push-fit capsules can contain the
active ingredients in admixture with filler such as lactose,
binders such as starches, and/or lubricants such as talc or
magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended
in suitable liquids, such as fatty oils, liquid paraffin, or liquid
polyethylene glycols. In addition, stabilizers may be added.
All formulations for oral administration should be in dosages suitable for such administration.
In one embodiment, the compounds of the present invention can be administered transdermally, such as through a
skin patch, or topically. In one aspect, the transdermal or
topical formulations of the present invention can additionally comprise one or multiple penetration enhancers or other
effectors, including agents that enhance migration of the
delivered compound. Transdermal or topical administration
could be preferred, for example, in situations in which
location specific delivery is desired.
For administration by inhalation, the compounds for use
according to the present invention are conveniently delivered in the form of an aerosol spray presentation from
pressurized packs or a nebulizer, with the use of a suitable
propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide, or
any other suitable gas. In the case of a pressurized aerosol,
the appropriate dosage unit may be determined by providing
a valve to deliver a metered amount. Capsules and cartridges
of, for example, gelatin, for use in an inhaler or insufllator
may be formulated. These typically contain a powder mix of
the compound and a suitable powder base such as lactose or
starch.
Compositions formulated for parenteral administration by
injection, e.g., by bolus injection or continuous infusion can
be presented in unit dosage form, e.g., in ampoules or in
multi-dose containers, with an added preservative. The
compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may
contain formulatory agents such as suspending, stabilizing
and/or dispersing agents. Formulations for parenteral administration include aqueous solutions or other compositions in
water-soluble form.
Suspensions of the active compounds may also be prepared as appropriate oily injection suspensions. Suitable
lipophilic solvents or vehicles include fatty oils such as
sesame oil and synthetic fatty acid esters, such as ethyl
oleate or triglycerides, or liposomes. Aqueous injection
suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl
cellulose, sorbitol, or dextran. Optionally, the suspension
may also contain suitable stabilizers or agents that increase
the solubility of the compounds to allow for the preparation
of highly concentrated solutions. Alternatively, the active
ingredient may be in powder form for constitution with a
suitable vehicle, e.g., sterile pyrogen-free water, before use.
As mentioned above, the compositions of the present
invention may also be formulated as a depot preparation.
Such long acting formulations may be administered by
implantation (for example, subcutaneously or intramuscu-
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larly) or by intramuscular injection. Thus, for example, the
present compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion
in an acceptable oil) or ion exchange resins, or as sparingly
soluble derivatives, for example, as a sparingly soluble salt.
Suitable carriers for the hydrophobic molecules of the
invention are well known in the art and include co-solvent
systems comprising, for example, benzyl alcohol, a nonpolar
surfactant, a water-miscible organic polymer, and an aqueous phase. The co-solvent system may be the VPD cosolvent system. VPD is a solution of3% w/v benzyl alcohol,
8% w/v of the nonpolar surfactant polysorbate 80, and 65%
w/v polyethylene glycol300, made up to volume in absolute
ethanol. The VPD co-solvent system (VPD:5W) consists of
VPD diluted 1: 1 with a 5% dextrose in water solution. This
co-solvent system is effective in dissolving hydrophobic
compounds and produces low toxicity upon systemic administration. Naturally, the proportions of a co-solvent system
may be varied considerably without destroying its solubility
and toxicity characteristics. Furthermore, the identity of the
co-solvent components may be varied. For example, other
low-toxicity nonpolar surfactants may be used instead of
polysorbate 80, the fraction size of polyethylene glycol may
be varied, other biocompatible polymers may replace polyethylene glycol, e.g., polyvinyl pyrrolidone, and other sugars or polysaccharides may substitute for dextrose.
Alternatively, other delivery systems for hydrophobic
molecules may be employed. Liposomes and emulsions are
well known examples of delivery vehicles or carriers for
hydrophobic drugs. Liposomal delivery systems are discussed above in the context of gene-delivery systems. Certain organic solvents such as dimethylsulfoxide also may be
employed, although usually at the cost of greater toxicity.
Additionally, the compounds may be delivered using sustained-release systems, such as semi-permeable matrices of
solid hydrophobic polymers containing the effective amount
of the composition to be administered. Various sustainedrelease materials are established and available to those of
skill in the art. Sustained-release capsules may, depending
on their chemical nature, release the compounds for a few
weeks up to over 100 days. Depending on the chemical
nature and the biological stability of the therapeutic reagent,
additional strategies for stabilization may be employed.
For any composition used in the present methods of
treatment, a therapeutically effective dose can be estimated
initially using a variety of techniques well known in the art.
For example, in a cell culture assay, a dose can be formulated in animal models to achieve a circulating concentration
range that includes the IC 50 as determined in cell culture.
Dosage ranges appropriate for human subjects can be determined, for example, using data obtained from cell culture
assays and other animal studies.
A therapeutically effective dose of an agent refers to that
amount of the agent that results in amelioration of symptoms
or a prolongation of survival in a subject. Toxicity and
therapeutic efficacy of such molecules can be determined by
standard pharmaceutical procedures in cell cultures or
experimental animals, e.g., by determining the LD 50 (the
dose lethal to 50% of the population) and the ED 5 0 (the dose
therapeutically effective in 50% of the population). The dose
ratio of toxic to therapeutic effects is the therapeutic index,
which can be expressed as the ratio LD 50 /ED 50 . Agents that
exhibit high therapeutic indices are preferred.
Dosages preferably fall within a range of circulating
concentrations that includes the ED 50 with little or no
toxicity. Dosages may vary within this range depending
upon the dosage form employed and the route of adminis-

tration utilized. The exact formulation, route of administration, and dosage should be chosen, according to methods
known in the art, in view of the specifics of a subject's
condition.
The amount of agent or composition administered will, of
course, be dependent on a variety of factors, including the
sex, age, and weight of the subject being treated, the severity
of the afl.liction, the manner of administration, and the
judgment of the prescribing physician.
The present compositions may, if desired, be presented in
a pack or dispenser device containing one or more unit
dosage forms containing the active ingredient. Such a pack
or device may, for example, comprise metal or plastic foil,
such as a blister pack. The pack or dispenser device may be
accompanied by instructions for administration. Compositions comprising a compound of the invention formulated in
a compatible pharmaceutical carrier may also be prepared,
placed in an appropriate container, and labeled for treatment
of an indicated condition.
These and other embodiments of the present invention
will readily occur to those of ordinary skill in the art in view
of the disclosure herein, and are specifically contemplated.
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EXAMPLES
The invention is further understood by reference to the
following examples, which are intended to be purely exemplary of the invention. The present invention is not limited
in scope by the exemplified embodiments, which are
intended as illustrations of single aspects of the invention
only. Any methods that are functionally equivalent are
within the scope of the invention. Various modifications of
the invention in addition to those described herein will
become apparent to those skilled in the art from the foregoing description. Such modifications fall within the scope
of the appended claims.
Example 1
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Synthesis of compound
2-methyl-1-(8-phenyl-octyl)-pyridinium bromide
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(8-Bromo-octyl)-benzene (1 mmol) was added to a solution of 2-picoline (3 mmol) in acetonitrile, and the solution
mixture was refluxed for 24 hours. The acetonitrile was
removed in a vacuum, and the resulting residue was partitioned between ether and water. The aqueous layer was
washed extensively with ether until no picoline was left in
the aqueous layer. The resulting aqueous solution of the
product was extracted with chloroform. The chloroform was
removed to afford the product (70%). 1 HNMR (300 MHz,
CDC13, ppm) 9.74 (d, lH), 8.35 (m, lH), 7.96 (m, lH), 7.86
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(d, lH), 7.15-7.25 (m, 4H), 4.92 (t, 2H), 2.95 (s, 3H),
1.88-1.98 (m, 2H), 1.54-1.64 (m, 2H), 1.39-1.49 (m, 2H),
1.25-1.38 (br, 6H).

The resulting aqueous solution of the product was extracted
with chloroform. The chloroform was removed to afford the
product (70%). 1 HNMR (300 MHz, CDC13, ppm), 9.50 (d,
lH), 7.70 (d, lH), 7.60 (s, lH), 7.10-7.30 (dd, lH), 4.78 (t,
2H), 2.84 (s, 3H), 2.54-2.60 (m, 5H), 1.80-1.92 (m, 2H),
1.50-1.60 (br, 2H), 1.20-1.45 (br, 6H).

Example 2

5

Synthesis of compound
3 -methy1-1-(8-pheny1-octyl )-pyridinium bromide

Example 4
Synthesis of compound
4-methyl-1-(8-phenyl-octyl)-pyridinium bromide
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(8-Bromo-octyl)-benzene (1 mmol) was added to a solution of 3-picoline (3 mmol) in acetonitrile, and the solution
refluxed for 24 hours. The acetonitrile was removed in a
vacuum and the resulting residue was partitioned between
ether and water. The aqueous layer was washed extensively
with ether until no pi co line was left in the aqueous layer. The
resulting aqueous solution of the product was extracted with
chloroform. The chloroform was removed to afford the
product (76%). 1 HNMR (300 MHz, CDC13, ppm) 9.40 (s,
lH), 9.22 (d, lH), 8.02 (d, lH), 7.96 (dd, lH), 7.12-7.22 (dd,
4H), 4.94 (t, 2H), 2.62 (s, 3H), 2.56 (t, 2H), 1.94-2.04 (m,
2H), 1.50-1.60 (m, 2H), 1.20-1.40 (br, 8H). 13 CNMR,
145.68, 144.65, 142.87, 142.37, 139.79, 128.55, 128.40,
127.89, 125.76, 62.20, 36.19, 32.29, 31.73, 29.53, 29.44,
29.33, 26.40, 19.11.
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Synthesis of compound
2,4-dimethyl-1-(8-phenyl-octyl)-pyridinium bromide
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(8-Bromo-octyl)-benzene (1 mmol) was added to a solution of 4-picoline (3 mmol) in acetonitrile, and the solution
was refluxed for 24 hours. The acetonitrile was removed in
vacuum and the resulting residue was partitioned between
ether and water. The aqueous layer was washed extensively
with ether until no picoline was left in the aqueous layer. The
resulting aqueous solution of the product was extracted with
chloroform. The chloroform was removed to afford the
product (78%). 1 HNMR (300 MHz, CDC13, ppm) 9.26 (d,
2H), 7.84 (d, 2H), 7.14-7.28 (dd, 4H), 4.90 (t, 2H), 2.62 (s,
3H), 2.56 (t, 2H), 1.92-2.02 (m, 2H), 1.50-1.60 (m, 2H),
1.20-1.40 (br, 8H). 13 CNMR, 158.92, 144.28, 142.86,
128.95, 128.56, 128.40, 125.76, 61.61, 36.19, 32.15, 31.71,
29.53, 29.42, 29.31, 26.37, 22.63.
Example 5
Synthesis of compound
1-dodec-7-ynyl-2-methyl-pyridinium iodide
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(8-Bromo-octyl)-benzene (1 mmol) was added to a solution of2,4-lutidine (3 mmol) in acetonitrile, and the solution
refluxed for 24 hours. The acetonitrile was removed in a
vacuum and the resulting residue was partitioned between
ether and water. The aqueous layer was washed extensively
with ether until no 2,4-lutidine was left in the aqueous layer.

65

12-Chloro-dodec-5-yne (1 mmol) was mixed with potassium iodide (3 mmol) and 2-picoline (3 mmol) in butanone.
room temperature. The butanone was removed in a vacuum,
and the resulting residue was partitioned between water and
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ethyl ether. The aqueous layer was washed extensively with
ether until no 2-picoline was left in the aqueous layer. The
resulting aqueous solution of the product was extracted with
chloroform. The chloroform was removed to afford the
product (85%). 1 HNMR (300 MHz, CDC13, ppm) 9.62 (d,
lH), 8.39 (dd, lH), 7.99 (m, lH), 7.91 (d, lH), 4.88 (t, 2H),
2.97 (s, 3H), 2.12-2.20 m, 4H), 1.90-2.00 (m, 2H), 1.32-1.58
(m, 8H), 0.88 (t, 3H).

The mixture was refluxed for 3 days and cooled to room
temperature, filtrated. The butanone was removed in a
vacuum, and the resulting residue was partitioned between
water and ethyl ether. The aqueous layer was washed
extensively with ether until no 4-picoline was left in the
aqueous layer. The resulting aqueous solution of the product
was extracted with chloroform. The chloroform was
removed to afford the product (87%). 1 HNMR (300 MHz,
CDC13, ppm), 9.28 (d, 2H), 7.92 (d, 2H), 4.92 (t, 2H), 2.68
(s, 3H), 1.96-2.18 (m, 6H), 1.32-1.50 (br, 10H), 0.88 (t, 3H).

Example 6
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Example 8
Synthesis of compound
1-dodec-7-ynyl-3-methyl-pyridinium iodide

Synthesis of compound
1-dodec-7 -ynyl-2,4-dimethyl-pyridinium iodide
15

KI!Butanone,
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12-Chloro-dodec-5-yne (1 mmol) was mixed with potassium iodide (3 mmol) and 3-picoline (3 mmol) in butanone.
The mixture was refluxed for 3 days and cooled to room
temperature, filtrated. The butanone was removed in a
vacuum, and the resulting residue was partitioned between
water and ethyl ether. The aqueous layer was washed
extensively with ether until no 3-picoline was left in the
aqueous layer. The resulting aqueous solution of the product
was extracted with chloroform. The chloroform was
removed to afford the product (82% ). 1 HNMR (300 MHz,
CDC13, ppm) 9.36 (s, lH), 9.18 (d, lH), 8.24 (d, lH), 8.00
(dd, lH), 4.92 (t, 2H), 2.62 (s, 3H), 1.95-2.18 (m, 6H),
1.15-1.25 (br, 10H), 0.90 (t, 3H); 13 CNMR, 145.51, 144.12,
144.78, 139.46, 127.56, 80.44, 79.42, 61.75, 31.72, 31.16,
28.65, 28.04, 25.52, 21.92, 18.75, 18.55, 18.40, 13.63.
Example 7
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Synthesis of compound
1-dodec-7-ynyl-4-methyl-pyridinium iodide

Example 9
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12-Chloro-dodec-5-yne (1 mmol) was mixed with potassium iodide (3 mmol) and 2,4-lutidine (3 mmol) in
butanone. The mixture was refluxed for 3 days and cooled to
room temperature, filtrated. The butanone was removed in a
vacuum, and the resulting residue was partitioned between
water and ethyl ether. The aqueous layer was washed
extensively with ether until no 2,4-lutidine was left in the
aqueous layer. The resulting aqueous solution of the product
was extracted with chloroform. The chloroform was
removed to afford the product (84%). 1 HNMR (300 MHz,
CDC13, ppm), 9.40 (d, lH), 7.75 (d, lH), 7.66 (s, lH), 4.78
(t, 3H), 2.88 (s, 3H), 2.60 (s, 3H), 2.05-2.15 (br, 4H),
1.80-2.00 (br, 2H), 1.30-1.50 (br, 10H), 0.86 (t, 3H);
13
CNMR, 156.73, 153.05, 145.84, 136.61, 127.27, 80.86,
79.85, 58.12, 31.54, 30.94, 39.09, 26.17, 22.39, 22.30,
21.03, 18.96, 18.79, 14.02.

Synthesis of compound
1-dodec-7 -ynyl-3,5-dimethyl-pyridinium iodide

55

N

Cl

KI!
Butanone,
reflux

u

N

KI/Butanone,
reflux

A

r~

65

12-Chloro-dodec-5-yne (1 mmol) was mixed with potassium iodide (3 mmol) and 4-picoline (3 mmol) in butanone.
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12-Chloro-dodec-5-yne (1 nnnol) was mixed with potassium iodide (3 nnnol) and 3,5-lutidine (3 nnnol) in
butanone. The mixture was refluxed for 3 days and cooled to
room temperature, filtrated. The butanone was removed in
vacuum, and the resulting residue was partitioned between
water and ethyl ether. The aqueous layer was washed
extensively with ether until no 3,5-lutidine was left in the
aqueous layer. The resulting aqueous solution of the product
was extracted with chloroform. The chloroform was
removed to afford the product (78% ). 1 HNMR (300 MHz,
CDC13, ppm), 9.06 (s, 2H), 8.00 (s, lH), 4.86 (t, 3H), 2.48
(s, 3H), 1.98-2.16 (m, 6H), 1.32-1.48 (br, 10H), 0.88 (t, 3H);
13
CNMR, 146.12, 141.38, 138.64, 80.43, 79.53, 61.46,
31.70, 31.17, 28.68, 28.07, 25.55, 21.92, 18.57, 18.42,
13.63.

-continued
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Example 10
Synthesis of compound
1-dodec-7 -ynyl-3,4-dimethyl-pyridinium iodide

20

12-Bromo-dodec-3-yne (1 nnnol) was added to a solution
of 2-picoline (3 nnnol) in acetonitrile, and the solution was
refluxed for 24 hours. The acetonitrile was removed in
vacuum, and the resulting residue was partitioned between
ether and water. The aqueous layer was washed extensively
with ether until no 2-picoline was left in the aqueous layer.
The resulting aqueous solution of the product was extracted
with chloroform. The chloroform was removed to afford the
product (70%). 1 HNMR (300 MHz, CDC13, ppm), 9.68 (d,
lH), 8.28 (m, lH), 7.96 (m, lH), 7.84 (d, lH), 4.94 (t, 2H),
2.98 (s, 3H), 2.05-2.20 (m, 4H), 1.88-2.00 (m, 2H), 1.201.60 (br, 10H), 1.10 (t, 3H).
Example 12
Synthesis of compound
1-dodec-9-ynyl-3-methyl-pyridinium bromide
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12-Chloro-dodec-5-yne (1 nnnol) was mixed with
Sodium iodide (3 nnnol) and 3,4-lutidine (3 nnnol) in
butanone. The mixture was refluxed for 3 days and cooled to
room temperature, filtrated. The butanone was removed in
vacuum, and the resulting residue was partitioned between
water and ethyl ether. The aqueous layer was washed
extensively with ether until no 3,4-lutidine was left in the
aqueous layer. The resulting aqueous solution of the product
was extracted with chloroform. The chloroform was
removed to afford the product (72% ). 1 HNMR, (300 MHz,
CDC13, ppm, ppm), 9.22 (s, lH), 9.04 (d, lH), 7.80 (d, lH),
4.84 (t, 3H), 2.52 (s, 3H), 2.50 (s, 3H), 1.92-2.14 (m, 6H),
1.28-1.45 (m, 10H), 0.84 (t, 3H). 13 CNMR, 157.84, 143.39,
141.81, 138.53, 128.72, 80.80, 79.90, 61.23, 32.03, 31.54,
29.08, 28.48, 25.91, 22.30, 20.78, 18.96, 18.79, 17.44,
14.02.
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12-Bromo-dodec-3-yne (1 nnnol) was added to a solution
of 3-picoline (3 nnnol) in acetonitrile, and the solution was
refluxed for 24 hours. The acetonitrile was removed in a
vacuum, and the resulting residue was partitioned between
ether and water. The aqueous layer was washed extensively
with ether until no picoline was left in the aqueous layer. The
resulting aqueous solution of the product was extracted with
chloroform. The chloroform was removed to afford the
product (70%). 1 HNMR (300 MHz, CDC13, ppm), 9.42 (s,
lH), 9.24 (d, lH), 8.24 (d, lH), 8.00 (dd, lH), 4.95 (t, 2H),
2.62 (s, 3H), 1.95-2.2 (m, 6H), 1.23-1.45 (br, 10H), 1.1 (t,
3H); 13 CNMR, 145.29, 144.24, 141.98, 139.42, 127.51,
81.57, 79.26, 61.83, 31.90, 28.95, 28.92, 28.82, 28.62,
26.02, 18.72, 18.63, 14.38, 12.40.
Example 13
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Example 11

Synthesis of compound
1-dodec-9-ynyl-4-methyl-pyridinium bromide

Synthesis of 1-dodec-9-ynyl-2-methyl-pyridinium
bromide
60
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12-Bromo-dodec-3-yne (1 mmol) was added to a solution
of 4-picoline (3 mmol) in acetonitrile, and the solution was
refluxed for 24 hours. The acetonitrile was removed in a
vacuum, and the resulting residue was partitioned between
ether and water. The aqueous layer was washed extensively
with ether until no pi co line was left in the aqueous layer. The
resulting aqueous solution of the product was extracted with
chloroform. The chloroform was removed to afford the
product (82%). 1 HNMR (300 MHz, CDC13, ppm), 9.24 (d,
2H), 7.86 (d, 2H), 4.90 (t, 2H), 2.64 (s, 3H), 1.95-2.16 (m,
6H), 1.26-1.34 (br, 10H), 0.88 (t, 3H).
Example 14
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Synthesis of
1-[ 4-(4-butyl-phenyl)-butyl]-2-methyl-pyridinium
bromide

25

1-(4-Bromo-butyl)-4-butyl-benzene (1 mmol) was added
to a solution of 3-picoline (3 mmol) in acetonitrile and the
solution refluxed for 24 hours. The acetonitrile was removed
in vacuum, and the resulting residue was partitioned
between ether and water. The aqueous layer was washed
extensively with ether until no picoline was left in the
aqueous layer. The resulting aqueous solution of the product
was extracted with chloroform. The chloroform was
removed to afford the product (75%). 1 HNMR (300 MHz,
CDC13, ppm), 9.32 (s, lH), 9.2 (d, 1=5.1, lH), 8.16 (d,
1=5.1, 7.91 (m, lH), 7.07 (d, 1=8.4, 2H), 7.02 (d, 1=8.4, 2H),
4.96 (t, 1=7.2, 2H), 2.52-2.64 (m, 7H), 2.00-2.06 (m, 2H),
1.60-1.70 (m, 2H), 1.60-1.60 (m, 2H), 1.29-1.36 (m, 2H),
0.90 (t, 1=7.2, 3H); 13 CNMR, 145.62, 144.71, 142.37,
140.84, 139.73, 138.32, 128.66, 128.48, 127.78, 61.82,
35.54, 34.95, 34.05, 31.71, 27.93, 22.72, 19.07, 14.33.
Example 16
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Synthesis of compound
1-[ 4-(4-butyl-phenyl)-butyl]-4-methyl-pyridinium
bromide

ACN,reflux

1-(4-Bromo-butyl)-4-butyl-benzene (1 mmol) was added
to a solution of 2-picoline (3 mmol) in acetonitrile, and the
solution was refluxed for 24 hours. The acetonitrile was
removed in a vacuum, and the resulting residue was partitioned between ether and water. The aqueous layer was
washed extensively with ether until no 2-picoline was left in
the aqueous layer. The resulting aqueous solution of the
product was extracted with chloroform. The chloroform was
removed to afford the product (74%). 1 HNMR (300 MHz,
CDC13, ppm), 9.69 (d, 1=6.6, lH), 8.25-8.30 (m, lH),
7.90-7.95 (m, lH), 7.77 (d, 1=7.8, lH), 7.04-7.10 (m, 4H),
4.92 (t, 7.5, 2H), 2.84 (s, 3H), 2.66 (t, 1=7.2, 2H), 2.56 (t,
1=7.5, 2H), 1.89-1.98 (m, 2H), 1.78-1.86 (m, 2H), 1.51-1.59
(m, 2H), 1.27-1.37 (m, 2H), 0.91 (t, 1=7.2, 3H).
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Example 15
Synthesis of compound
1-[ 4-(4-butyl-phenyl)-butyl]-3-methyl-pyridinium
bromide

Br
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1-(4-Bromo-butyl)-4-butyl-benzene (1 mmol) was added
to a solution of 4-picoline (3 mmol) in acetonitrile, and the
solution was refluxed for 24 hours. The acetonitrile was
removed in a vacuum, and the resulting residue was partitioned between ether and water. The aqueous layer was
washed extensively with ether until no picoline was left in
the aqueous layer. The resulting aqueous solution of the
product was extracted with chloroform. The chloroform was
removed to afford the product (72%). 1 HNMR (300 MHz,
CDC13, ppm), 9.22 (d, 1=6.6, 2H), 7.79 (d, 1=6.6, 2H), 7.05
(d, 1=8.4, 2H), 7.02 (d, 1=8.4, 2H), 4.90 (t, 1=7.5, 3H),
2.51-2.63 (m, 7H), 1.96-2.06 (m, 2H), 1.58-1.68 (m, 2H),
1.51-1.61 (m, 2H), 1.31-1.37 (m, 2H), 0.89 (t, 1=7.2, 3H);
13
CNMR, 158.91, 144.31, 140.83, 138.30, 128.92, 128.66,
128.45, 61.26, 35.54, 34.95, 34.04, 31.61, 27.95, 22.73,
22.57, 14.33.
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Example 17

Example 19

Synthesis of 2-[ 4-(4-butyl-phenyl)-butyl]-5,6, 7,8tetrahydro-isoquinolinium bromide

Synthesis of compound 1-[4-(4-butyl-phenyl)-butyl]-2,4-dimethyl-pyridinium bromide
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1-(4-Bromo-butyl)-4-butyl-benzene (1 mmol) was added
to a solution oftetrahydroisoquinoline (2 mmol) in acetonitrile, and the solution was refluxed for 24 hours, The
acetonitrile was removed in vacuum, and the resulting
residue was partitioned between ether and water, The aqueous layer was washed extensively with ether until no tetrahydroisoquinoline was left in the aqueous layer, The resulting aqueous solution of the product was extracted with
chloroform, The chloroform was removed to afford the
product (72%), 1 HNMR (300 MHz, CDC13, ppm), 9,12 (s,
lH), 8,85 (d, 1=6,0, lH), 7,61 (d, 1=6,0, lH), 7,02-7,08 (m,
4H), 4,83 (t, 7,5, 3H), 2,92-2,94 (m, 4H), 2,61 (t, 1=7,5, 2H),
2,54 (t, 1=7,5, 2H), L90-2,04 (m, 2H), L80-L90 (m, 4H),
L62-L69 (m, 2H), L53-L62 (m, 2H), L29-L37 (m, 2H),
0,90 (t, 1=7,2, 3H), 13 CNMR, 157,94, 144,18, 140,82,
140,64, 138,96, 138,37, 128,65, 128A8, 127,99, 6U6,
35,54, 34,99, 34,05, 3L56, 29,92, 27,98, 26,69, 22,74,
2L37, 14,33,
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1-(4-Bromo-butyl)-4-butyl-benzene (1 mmol) was added
to a solution of2,4-lutidine (3 mmol) in acetonitrile, and the
solution was refluxed for 24 hours, The acetonitrile was
removed in a vacuum, and the resulting residue was partitioned between ether and water, The aqueous layer was
washed extensively with ether until no lutidine left in the
aqueous layer, The resulting aqueous solution of the product
was extracted with chloroform, The chloroform was
removed to afford the product (79%), 1 HNMR (300 MHz,
CDC13, ppm), 9,51 (d, 1=6,2, lH), 7,67 (d, 1=6,2, lH), 7,54
(s, lH), 7,05-7,07 (m, 4H), 4,83 (t, 1=7,2, 2H), 2,77 (s, 3H),
2,64 (t, 1=7,2, 2H), 2,52-2,58 (m, 5H), L87-L92 (m, 2H),
L76-L82 (m, 2H), L50-L58 (m, 2H), L29-L37 (m, 2H),
0,91 (t, 1=7,8, 3H),

Example 18
Example 20
Synthesis of 1-[4-( 4-butyl-phenyl)-butyl]-3-(3-hydroxy-propyl)-pyridinium bromide

~Br
f '\

OJ
Nn

40

Synthesis of 1-[4-( 4-butyl-phenyl)-butyl]-3,4-dimethyl-pyridinium bromide

OH

N::,.

45

ex

N

ACN,reflux

Br

ACN,reflux

~OH5o

1-(4-Bromo-butyl)-4-butyl-benzene (1 mmol) was added
to a solution of hydroxypropanylpyridine (2 mmol) in
acetonitrile, and the solution was refluxed for 24 hours, The
acetonitrile was removed in a vacuum, and the resulting
residue was partitioned between ether and water, The aqueous layer was washed extensively with ether until no
hydroxypropanylpyridine was left in the aqueous layer, The
resulting aqueous solution of the product was extracted with
chloroform, The chloroform was removed to afford the
product (65%), 1 HNMR (300 MHz, CDC13, ppm), 9A1 (s,
lH), 8,85 (d, 1=6,3, lH), 8,26 (d, 1=8,1, lH), 7,89 (dd, 1=6,3,
1=8,1, lH), 7,02-7,07 (m, 4H), 4,90 (t, 1=7,5, 2H), 3,59 (t,
1=5A, 2H), 3,00 (t, 1=6,9, 2H), 2,62 (t, 1=7,2, 2H), 2,55 (t,
1=7,8, 2H), L95-2,05 (m, 4H), L57-L69 (m, 2H), L50-L60
(m, 2H), L29-L37 (m, 2H), 0,90 (t, 1=7,2, 3H),

55

60

65

1-(4-Bromo-butyl)-4-butyl-benzene (1 mmol) was added
to a solution of3,4-lutidine (3 mmol) in acetonitrile, and the
solution was refluxed for 24 hours, The acetonitrile was
removed in a vacuum, and the resulting residue was partitioned between ether and water, The aqueous layer was
washed extensively with ether until no lutidine left in the
aqueous layer, The resulting aqueous solution of the product
was extracted with chloroform, The chloroform was
removed to afford the product (79%), 1HNMR (300 MHz,
CDC13, ppm), 9,20 (s, lH), 9,03 (d, 1=6,3, lH), 7,72 (d,
1=6,3, lH), 7,00-7,07 (m, 4H), 4,87 (t, 1=7,5, 2H), 2,60 (t,
1=7,8, 2H), 2,54 (t, 1=7,8, 2H), 2A9 (s, 3H), 2A6 (s, 3H),
L99-2,04 (m, 2H), L50-L66 (m, 4H), L28-L36 (m, 2H),

US 9,550,753 B2
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0.90 (t, 1=7.5, 3H). 13 CNMR 157.60, 143.56, 141.92,
140.78, 138.40, 128.63, 128.57, 128.47, 61.00, 35.54, 34.98,
34.04, 31.59, 27.96, 22.73, 20.66, 17.36, 14.31.

washed extensively with ether until no picoline was left in
the aqueous layer. The resulting aqueous solution of the
product was extracted with chloroform. The chloroform was
removed to afford the product (77% ). 1 HNMR R (300 MHz,
CDC13, ppm), 9.48 (s, lH), 9.33 (d, 1=6.6, lH), 8.24 (d,
1=7.2, lH), 7.93 (dd, 1=6.6, 1=7.2, lH), 7.16 (d, 1=8.2, 2H),
7.06 (d, 1=8.2, 2H), 5.21 (t, 1=6.0, 2H), 3.26 (t, 1=6.0, 2H),
2.59 (s, 3H), 2.56 (t, 2H), 1.49-1.59 (m 2H), 1.25-1.37 (m,
2H), 0.9 (t, 1=7.2, 3H); 13 CNMR, 145.70, 144.78, 143.64,
142.26, 138.98, 131.15, 128.32, 126.94, 118.92, 85.84,
82.45, 59.90, 35.45, 33.28, 22.81. 22.24, 18.71, 13.89.

Example 21

5

Synthesis of 1-[4-(4-butyl-phenyl)-butyl]-3,5-dimethyl-pyridinium bromide
10

~

Br

[~

Example 23
15

ACN,reflux

Synthesis of compound 1-[ 4-(4-butyl-phenyl)-but-3yny1]-4-methy1-pyridinium bromide

0

Br

1-(4-Bromo-butyl)-4-butyl-benzene (1 mmol) was added
to a solution of3,5-lutidine (3 mmol) in acetonitrile, and the
solution was refluxed for 24 hours. The acetonitrile was
removed in a vacuum, and the resulting residue was partitioned between ether and water. The aqueous layer was
washed extensively with ether until no lutidine was left in
the aqueous layer. The resulting aqueous solution of the
product was extracted with chloroform. The chloroform was
removed to afford the product (81% ). 1HNMR (300 MHz,
CDC13, ppm), 9.11 (s, 2H), 7.92 (s, lH), 7.00-7.06 (m, 4H),
4.88 (t, 1=7.5, 2H), 2.51-2.62 (m, 7H), 1.99-2.05 (m, 2H),
1.49-1.66 (m, 4H), 1.28-1.35 (m, 2H), 0.89 (t, 1=7.2, 3H).
13
CNMR, 146.17, 141.96, 140.81, 138.91, 138.40, 128.63,
128.48, 61.60, 35.54, 34.98, 34.05, 31.68, 27.95, 22.72,
18.88, 14.31.
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Example 22
Synthesis of compound 1-[4-(4-butyl-phenyl)-but-3ynyl]-3-methyl-pyridinium bromide
45

50

1-(4-Bromo-but-1-ynyl)-4-butyl-benzene (1 mmol) was
added to a solution of 4-picoline (3 mmol) in acetonitrile,
and the solution was refluxed for 24 hours. The acetonitrile
was removed in vacuum, and the resulting residue was
partitioned between ether and water. The aqueous layer was
washed extensively with ether until no picoline was left in
the aqueous layer. The resulting aqueous solution of the
product was extracted with chloroform. The chloroform was
removed to afford the product (67%). 1 HNMR (300 MHz,
CDC13, ppm), 9.40 (d, 1=6.9, lH), 7.80 (d, lH), 7.17 (d,
1=7.8, 2H), 7.06 (d, 1=7.8, 2H), 5.2 (t, 2H), 3.23 (t, 2H), 2.65
(s, 3H), 2.56 (t, 1=7.8, 2H), 1.49-1.57 (m, 2H), 1.27-1.35 (m,
2H), 0.90 (t, 1=7.5, 3H).

ACN,reflux

Q

Example 24
55

Synthesis of 1-[4-(4-butyl-phenyl)-but-3-ynyl]-3ethyl-pyridinium bromide

N

~

e

Br

60

1-(4-Bromo-but-1-ynyl)-4-butyl-benzene (1 mmol) was
added to a solution of 3-picoline (3 mmol) in acetonitrile,
and the solution was refluxed for 24 hours. The acetonitrile
was removed in a vacuum, and the resulting residue was
partitioned between ether and water. The aqueous layer was

65

ACN,reflux
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Example 26

~

Synthesis of 1-[4-( 4-butyl-phenyl)-but-3-ynyl]-3,4dimethyl-pyridinium bromide

~~
e

Br

Br
10

1-(4-Bromo-but-1-ynyl)-4-butyl-benzene (1 mmol) was
added to a solution of 3-ethylpyridine (3 mmol) in acetonitrile, and the solution was refluxed for 24 hours. The
acetonitrile was removed in vacuum, and the resulting
residue was partitioned between ether and water. The aqueous layer was washed extensively with ether until no ethylpyridine was left in the aqueous layer. The resulting
aqueous solution of the product was extracted with chloroform. The chloroform was removed to afford the product
(67%). lHNMR (300 MHz, CDC13, ppm), 9.43 (d, 1=6.0,
lH), 9.41 (s, lH), 8.25 (d, 1=8.1, lH), 7.96 (dd, 1=6.0, 1=8.1,
lH), 7.15 (d, 1=8.1, 2H), 7.06, d, 1=8.1, 2H), 5.26 (t, 1=6.0,
2H), 3.26 (t, 1=6.0, 2H), 2.90 (q, 1=7.5, 2H), 2.56 (t, 1=8.1,
2H), 1.49-1.59 (m, 2H), 1.27-1.37 (m, 5H), 0.90 (t, 1=7.2,
3H); 13 CNMR, 144.65, 144.46, 144.14, 143.65, 142.45,
131.14, 128.30, 127.12, 118.87, 85.88, 82.45, 59.99, 35.45,
33.27, 26.01, 22.85, 22.21, 14.26, 13.88.

cc

----=--------'-•

cc

ACN,reflux

N
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Example 25
30

Synthesis of 2-[ 4-(4-butyl-phenyl)-but-3-ynyl]-5,6,
7,8-tetrahydro-isoquinolinium bromide

1-(4-Bromo-but-1-ynyl)-4-butyl-benzene (1 mmol) was
added to a solution of 3-hydroxypropanylpyridine (2 mmol)
in acetonitrile, and the solution was refluxed for 24 hours.
The acetonitrile was removed in a vacuum, and the resulting
residue was partitioned between ether and water. The aqueous layer was washed extensively with ether until no
hydroxypropanylpyridine was left in the aqueous layer. The
resulting aqueous solution of the product was extracted with
chloroform. The chloroform was removed to afford the
product (60%). lHNMR (300 MHz, CDC13, ppm), 9.39 (s,
lH), 9.13 (d, 1=6.3, lH), 7.70 (d, 1=6.3, lH), 7.17 (d, 1=8.1,
2H), 7.07 (d, 1=8.1, 2H), 5.13 (t, 1=6.0, 2H), 3.23 (t, 1=6.0,
2H), 2.57 (t, 1=7.8, 2H), 2.53 (s, 3H), 2.48 (s, 3H), 1.50-1.58
(m, 2H), 1.28-1.37 (m, 2H), 0.90 (t, 1=7.2, 3H); 13 CNMR,
158.19, 143.98, 138.11, 131.53, 128.69, 128.05, 119.45,
83.11, 59.60, 35.84, 33.64, 23.12, 22.62, 20.77, 17.35,
14.23.
Example 27

co

Br
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Synthesis of 1-[4-( 4-butyl-phenyl)-but-3-ynyl]-3,5dimethyl-pyridinium bromide

N

ACN,reflux
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1-(4-Bromo-but-1-ynyl)-4-butyl-benzene (1 mmol) was
added to a solution of tetrahydroisoquinoline (2 mmol) in
acetonitrile, and the solution was refluxed for 24 hours. The
acetonitrile was removed in a vacuum, and the resulting
residue was partitioned between ether and water. The aqueous layer was washed extensively with ether until no tetrahydroisoquinoline was left in the aqueous layer. The resulting aqueous solution of the product was extracted with
chloroform. The chloroform was removed to afford the
product (68%). lHNMR (300 MHz, CDC13, ppm), 9.30 (s,
lH), 9.04 (d, 1=6.3, 2H), 7.62 (d, 1=6.3, lH), 7.18 (d, 1=8.4,
2H), 7.06 (d, 1=8.4, 2H), 5.10 (t, 1=6.0, 3.21 (t, 1=6.0, 2H),
2.94-2.96 (m, 2H), 2.56 (t, 1=8.1, 2H), 1.81-1.87 (m, 2H),
1.49-1.56 (m, 2H), 1.27-1.34 (m, 2H), 0.89 (t, 1=7.2, 3H);
13
CNMR, 158.51, 144.59, 143.95, 140.93, 138.61, 131.55,
128.71, 127.57, 119.46, 85.97, 83.23, 59.58, 35.86, 33.69,
31.01, 26.70, 23.12, 22.63, 21.37, 14.28.
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A

~~
1-(4-Bromo-but-1-ynyl)-4-butyl-benzene (1 mmol) was
added to a solution of 3,5-lutidine (2 mmol) in acetonitrile,
and the solution was refluxed for 24 hours. The acetonitrile
was removed in a vacuum, and the resulting residue was
partitioned between ether and water. The aqueous layer was
washed extensively with ether until no lutidine was left in
the aqueous layer. The resulting aqueous solution of the
product was extracted with chloroform. The chloroform was
removed to afford the product (80%). 1HNMR (300 MHz,
CDC13, ppm), 9.39 (s, lH), 9.13 (d, 1=6.3, lH), 7.70 (d,
1=6.3, lH), 7.17 (d, 1=8.1, 2H), 7.07 (d, 1=8.1, 2H), 5.13 (t,
1=6.0, 2H), 3.23 (t, 1=6.0, 2H), 2.57 (t, 1=7.8, 2H), 2.53 (s,
3H), 2.48 (s, 3H), 1.50-1.58 (m, 2H), 1.28-1.37 (m, 2H),
0.90 (t, 1=7.2, 3H); 13 CNMR, 158.19, 143.98, 138.11,
131.53, 128.69, 128.05, 119.45, 83.11, 59.60, 35.84, 33.64,
23.12, 22.62, 20.77, 17.35, 14.23.
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Example 28

The acetonitrile was removed in vacuum, and the resulting
residue was partitioned between ether and water. The aqueous layer was washed extensively with ether until no
hydroxypropanylpyridine was left in the aqueous layer. The
resulting aqueous solution of the product was extracted with
chloroform. The chloroform was removed to afford the
product (60%). lHNMR (300 MHz, CDC13, ppm), 9.46 (s,
lH), 9.04 (d, 1=6.0, lH), 8.33 (d, 1=8.1, lH), 7.92 (dd, 1=6.0,
1=8.1, lH), 7.16 (d, 1=8.4, 2H), 7.04 (d, 1=8.1, 2H), 5.12 (t,
1=6.6, 2H), 3.57 (t, 6.0, 2H), 3.22 (t, 1=6.0, 2H), 2.98 (t,
1=7.2, 2H), 2.54 (t, 1=7.5, 3H), 1.94 (p, 6.0, 2H), 1.47-1.57
(m, 2H), 1.26-1.34 (m, 2H), 0.89 (t, 1=7.5, 3H); 13 CNMR,
145.54, 144.99, 143.62, 141.83, 131.20, 128.32, 126.94,
118.95, 85.65, 82.43, 59.92, 59.78, 58.26, 35.44, 33.28,
32.33, 29.24, 22.68, 22.23, 18.39, 13.88.

Synthesis of 1-[4-(4-butyl-phenyl)-but-3-ynyl]-3-(3hydroxy-propyl)-pyridinium bromide
5

~Br

OJOH
10
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Example 29
1-(4-Bromo-but-1-ynyl)-4-butyl-benzene (1 mmol) was
added to a solution of3-hydroxypropanylpyridine (2 mmol)
in acetonitrile, and the solution was refluxed for 24 hours.

20

Synthesis of compound
3-methyl-1-(13-pyridin-3-yl-tridecyl)-pyridinium
bromide

0(

J~

Br

35
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3-(13-Bromo-tridecyl)-pyridine (1 mmol) was added to
3-picoline (5 ml), and the mixture was heated at 50 C
overnight. The excess picoline was removed in vacuum, and
the resulting residue was partitioned between water and
ether. The aqueous layer was washed extensively with ether
until no picoline left in the aqueous layer, and then the
aqueous layer was extracted with chloroform. The chloroform was removed to afford the product (65%). 1 HNMR
(300 MHz, CDC13, ppm), 9.36 (s, lH), 9.22 (d, 1=5.4, lH),
8.44 (br, 2H), 8.21 (d, 1=7.5, lH), 7.97 (m, lH), 7.54 (d, 7.2,
lH), 7.24-7.24 m, lH), 4.96 (t, 1=7.2, 2H), 2.58-2.65 M,
5H), 2.00-2.07 (m, 4H), 1.58-1.60 (m, 2H), 1.20-1.36 (m,
16H); 13 CNMR, 148.76, 146.10, 145.58, 144.77, 142.38,
139.83, 137.29, 127.80, 123.98, 62.28, 58.71, 33.31, 32.36,
31.32, 29.80, 29.74, 29.64, 29.38, 29.35, 26.45, 19.15,
18.81.
Example 30
Synthesis of compound 3,4-dimethyl-1-(13-pyridin3-yl-tridecyl)-pyridinium bromide

Br

&
N

US 9,550,753 B2

36

35
-continued

I#
CC
.~

10

3-(13-Bromo-tridecyl)-pyridine (1 mmol) was added to
until no 3,5-lutidine was left in the aqueous layer, and then
3,4-lutidine (5 ml), and the mixture was heated at 50 C
the aqueous layer was extracted with chloroform. The chloovernight. The excess picoline was removed in a vacuum,
roform was removed to afford the product (62%). 1 HNMR
and the resulting residue was partitioned between water and
(300 MHz, CDC13, ppm), 9.10 (s, 2H), 8.45 (br, 2H), 7.96
ether. The aqueous layer was washed extensively with ether
until no 3,4-lutidine was left in the aqueous layer, and then 15 (s, lH), 7.57 (d, 1=7.5, lH), 7.24-7.27 (m, lH), 4.89 (t,
the aqueous layer was extracted with chloroform. The chlo1=7.5, 2H), 2.59-2.54 (m, SH), 1.99-2.04 (m, 2H), 1.57-1.62
roform was removed to afford the product (60%). 1 HNMR
(m, 2H), 1.21-1.38 (m, ISH), 13 CNMR, 148.07, 146.11,
(300 MHz, CDC13, ppm), 9.23 (s, lH), 9.04 (d, 1=6.3, lH),
8.40 (br, 2H), 7.79 (d, 1=6.0, lH), 7.48 (d, 8.1, lH),
145.45, 141.94, 139.01, 137.96, 124.16, 62.13, 58.74, 33.29,
7.18-7.20 (m, lH), 4.83 (t, 1=7.5, 2H), 2.58 (t, 1=7.5, 2H), 20
32.34, 31.26, 29.76, 29.73, 29.62, 29.39, 29.30, 26.49,
2.52 (s, 3H), 2.49 (s, 3H), 2.21 (br, lH), 1.82-2.02 (m, 2H),
18.98, 18.82.
1.54-1.62 (m, 2H), 1.15-1.35 (br, 12H). 13 CNMR, 157.61,
149.68, 146.92, 143.35, 141.91, 138.45, 138.33, 136.32,
128.65, 123.57, 61.37, 33.31, 32.19, 31.41, 29.85, 29.80,
Example 32
29.68, 29.41, 26.45, 20.69, 17.40.
25
Example 31
Synthesis of compound 2-(13-pyridin-3-yl-tridecyl)5,6,7,8-tetrahydro-isoquinolinium bromide

Synthesis of compound 3,5-dimethyl-1-(13-pyridin3-yl-tridecyl)-pyridinium bromide

Br

3-(13-Bromo-tridecyl)-pyridine (1 mmol) was added to
3,5-lutidine (5 ml), and the mixture was heated at 50 C
overnight. The excess picoline was removed in a vacuum,
and the resulting residue was partitioned between water and
ether. The aqueous layer was washed extensively with ether
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3-(13-Bromo-tridecyl)-pyridine (1 mmol) was added to
5,6,7,8-tetrahydro-isoquinoline (5 ml), and the mixture was
heated at 50 C overnight. The resulting residue was treated
with ether, and the ether was decanted after deposition for
30'. The residue was partitioned between water and ether.
The aqueous layer was washed extensively with ether, and
then the aqueous layer was extracted with chloroform. The
chloroform was removed to afford the product (62%).
1
HNMR (300 MHz, CDC13, ppm), 9.22 (s, lH), 8.90 (d,
1=6.3, lH), 8.44 (br, 2H), 7.67 (d, 1=6.3, lH), 7.55 (d, 8.1,
7.24-7.28 (m, lH), 4.83 (t, 1=7.2, 2.98-3.01 (m, 4H), 2.60 (t,
1=7.8, 2H), 1.94-2.02 (m, 2H), 1.87-1.90 (m, 4H), 1.56-1.60
(m, 2H), 1.19-1.35 (br, 20H); 13 CNMR, 157.87, 148.79,
146.13, 144.20, 140.68, 138.95, 138.80, 137.26, 128.08,
123.92, 61.40, 58.62, 33.30, 32.20, 31.34, 29.94, 29.82,
29.77, 29.67, 29.42, 29.36, 26.71, 26.46, 21.40, 18.81.

-continued
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Example 33
Synthesis of compound 5-(1,1'-biphenyl-4-yl)-pent4-yn-1-ol
20

Br

-

25

OH

5-(1,1'-biphenyl-4-yl)-4-pentyn-1-ol (3.40 g, 14.39
mmol) and carbon tetrabromide (6.21 g, 18.71 mmol) were
dissolved in dry methylene chloride (20 mL) and cooled to
oo C. Triphenylphosphine (5.15 g, 19.65 mmol) in methy lene chloride ( 10 mL) was added dropwise, and the mixture
was stirred for 1 h at oo C. The mixture was poured into
hexanes (100 mL), and then filtered through a short silica gel
colunm, washed with ethylacetatelhexanes (1/4). The combined organic solvents were evaporated to dryness under
reduced pressure. The resulting residue was purified by
colunm chromatography (hexanes:ethylacetate 30:1) to
afford 4.20 g of the title compound. Yield: 97%. 1 H NMR
(300 MHz, CDC1 3 ) o 2.15 (m, 2H), 2.63 (t, 1=6.9 Hz, 2H),
3.60 (t, 1=6.3 Hz, 2H), 7.32-7.60 (m, 9H) ppm; 13 C NMR
(75 MHz, CDC1 3 ) o 18.5, 31.8, 32.8, 81.7, 88.8, 122.6,
127.0, 127.1, 127.6, 128.9, 132.1, 140.5, 140.6 ppm.
Example 35

30

Synthesis of compound 1-[5-(1,1'-biphenyl-4-yl)pent -4-yny1]-2-methy1-pyridinium bromide
35

Br

4-Bromobiphenyl (10.28 g, 44.10 mmol), 4-pentyn-1-ol
(4.45 g, 52.92 mmol), and bis(triphenylphosphine)palladium
(II) dichloride (310 mg, 0.44 mmol) were stirred in triethylamine (100 mL) under nitrogen for 5 min. Copper(!)
iodide (42 mg, 0.22 mmol) was added, and the mixture was
stirred for 4 hrs at 65° C. The mixture was cooled to room
temperature and filtered through a celite pad, rinsed with
ethylacetate. The combined filtrate was evaporated to dryness under reduced pressure. The resulting residue was
purified by colunm chromatography (hexanes:ethylacetate
3:2) to afford 7.78 g of the title compound. Yield: 75%. 1 H
NMR (300 MHz, CDC1 3 ) o 1.88 (m, 2H), 2.57 (t, 1=6.9 Hz,
2H), 3.84 (t, 1=6.0 Hz, 2H), 7.32-7.60 (m, 9H) ppm; 13 C
NMR (75 MHz, CDC1 3 ) o16.4, 31.7, 62.1, 81.2, 90.2, 122.8,
127.0, 127.1, 127.6, 128.9, 132.0, 140.1 ppm.
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Example 34
Synthesis of compound
4-(5-bromo-pent-1-ynl)-1, 1'-biphenyl

OH
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A mixture of 4-(5-bromo-1-pentynl)-1,1'-biphenyl (357
mg, 1.19 mmol) and 2-picoline (1 mL) was heated at 60-70°
C. for 12 hrs. The resulted mixture was washed with diethyl
ether and then dissolved in water (15 mL). The aqueous
solution was extracted with diethyl ether (30 mLx3). Water
was removed by lyophilization to afford 393 mg of the title
compound. Yield: 84%. 1 H NMR (300 MHz, CDC1 3 ) o2.31
(m, 2H), 2.75 (t, 1=6.3 Hz, 2H), 3.04 (s, 3H), 5.14 (t, 1=7.8
Hz, 2H), 7.30-7.59 (m, 9H), 7.94-8.01 (m, 2H), 8.38 (t,
1=7.8 Hz, lH), 9.82 (d, 1=6.0 Hz, lH) ppm; 13 C NMR (75
MHz, CDC1 3 ) o 16.9, 21.1, 29.7, 57.2, 82.4, 88.1, 121.8,
126.4, 127.0, 127.1, 127.7, 128.9, 130.3, 132.0, 140.1,
140.8, 145.3, 146.8, 154.6 ppm.
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Example 36

compound. Yield: 92%. 1 H NMR (300 MHz, CDC1 3 ) o 2.40
(m, 2H), 2.49 (s, 3H), 2.67 (t, 1=6.6 Hz, 2H), 5.16 (t, 1=6.9
Hz, 2H), 7.30-7.59 (m, 9H), 7.80 (d, 1=6.3 Hz, 2H), 9.43 (d,
1=6.3 Hz, 2H) ppm; 13 C NMR (75 MHz, CDC1 3 ) o 16.8,
22.4, 30.3, 60.3, 82.3, 88.0, 121.9, 126.9, 127.0, 127.8,
128.8, 129.0, 132.0, 140.1, 140.7, 144.5, 159.2 ppm.

Synthesis of compound 1-[5-(1,1'-biphenyl-4-yl)pent-4-ynyl]-3-methyl-pyridinium bromide
5

Br

Example 38

-t)
Br

0

10

Synthesis of compound 1-[5-(1,1'-biphenyl-4-yl)pent-4-ynyl]-2,4-dimethyl-pyridinium bromide
15

Br

--

20

A mixture of 4-(5-bromo-1-pentynl)-1,1'-biphenyl (377
mg, 1.26 mmol) and 3-picoline (1 mL) was heated at 60-70°
C. for 12 hrs. The resulting mixture was washed with diethyl
ether and then dissolved in water (15 mL). The aqueous
solution was extracted with diethyl ether (30 mLx3). Water
was removed by lyophilization to afford 433 mg of the title
compound. Yield: 88%. 1 H NMR (300 MHz, CDC1 3 ) o2.43
(m, 2H), 2.58 (s, 3H), 2.67 (t, 1=6.6 Hz, 2H), 5.16 (t, 1=6.9
Hz, 2H), 7.30-7.61 (m, 9H), 7.98 (dd, 1=8.1, 6.0 Hz, lH),
8.16 (d, 1=8.1 Hz, lH), 9.37 (d, 1=6.0 Hz, lH), 9.50 (s, lH)
ppm; 13 C NMR (75 MHz, CDC1 3 ) o 16.8, 19.0, 30.5, 60.9,
82.4, 88.0, 121.9, 126.9, 127.7, 127.8, 128.9, 132.0, 139.7,
140.1, 140.7, 142.5, 144.8, 145.8 ppm.

25

30

Br

35

Example 37
Synthesis of compound 1-[5-(1,1'-biphenyl-4-yl)pent-4-ynyl]-4-methyl-pyridinium bromide

40

45

Br

--

0

A mixture of 4-(5-bromo-1-pentynl)-1,1'-biphenyl (328
mg, 1.10 mmol) and 2,4-lutidine (1 mL) was heated at
60-70° C. for 12 hrs. The resulting mixture was washed with
diethyl ether, and then dissolved in water (15 mL). The
aqueous solution was extracted with diethyl ether (30
mLx3). Water was removed by lyophilization to afford 360
mg of the title compound. Yield: 81%. 1 H NMR (300 MHz,
CDC1 3 ) o2.29 (m, 2H), 2.51 (s, 3H), 2.73 (t, 1=6.3 Hz, 2H),
2.96 (s, 3H), 5.04 (t, 1=7.5 Hz, 2H), 7.30-7.60 (m, 9H), 7.70
(s, 2H), 9.56 (d, 1=7.2 Hz, lH) ppm; 13 C NMR (75 MHz,
CDC1 3 ) o 16.8, 20.7, 22.1, 29.4, 56.4, 82.2, 88.1, 121.8,
126.9, 127.0, 127.7, 128.9, 130.5, 131.9, 140.0, 140.7,
145.8, 153.3, 158.7 ppm.

50

Example 39
Synthesis of compound 1-[5-(1,1'-biphenyl-4-yl)pent-4-ynyl]-3,4-dimethyl-pyridinium bromide

Br

0

Br

60

A mixture of 4-(5-bromo-1-pentynl)-1,1'-biphenyl (360
mg, 1.20 mmol) and 4-picoline (1 mL) was heated at 60-70°
C. for 12 hrs. The resulted mixture was washed with diethyl
ether and then dissolved in water (15 mL). The aqueous
solution was extracted with diethyl ether (30 mLx3). Water
was removed by lyophilization to afford 435 mg of the title

I
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-continued

Example 41
Synthesis of compound 1-[5-(1,1'-biphenyl-4-yl)pent-4-ynyl]-quinolinium bromide
Br

e
Br

-

10

A mixture of 4-(5-bromo-1-pentynl)-1,1'-biphenyl (327
mg, 1.09 mmol) and 3,4-lutidine (1 mL) was heated at
60-70° C. for 12 hrs. The resulted mixture was washed with
diethyl ether and then dissolved in water (15 mL). The
aqueous solution was extracted with diethyl ether (30
mLx3). Water was removed by lyophilization to afford 380
mg of the title compound. Yield: 86%. 1 H NMR (300 MHz,
CDC1 3 ) o 2.36 (s, 3H), 2.43 (s, 3H), 2.55 (m, 2H), 2.69 (t,
1=6.6 Hz, 2H), 5.10 (t, 1=6.6 Hz, 2H), 7.28-7.59 (m, 9H),
7.77 (d, 1=6.0 Hz, lH), 9.22 (d, 1=6.0 Hz, lH), 9.38 (s, lH)
ppm; 13 C NMR (75 MHz, CDC1 3 ) o 16.8, 17.2, 20.4, 30.2,
60.1, 82.0, 88.2, 122.0, 126.9, 127.7, 128.5, 128.9, 131.9,
138.2, 140.0, 140.6, 142.1, 143.7, 157.9 ppm.

~

8

N
20
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Synthesis of compound 1-[5-(1,1'-biphenyl-4-yl)pent-4-ynyl]-3,5-dimethyl-pyridinium bromide

35

Br

40

Br

e

#

25

Example 40

-

#

15

A mixture of 4-(5-bromo-1-pentynl)-1,1'-biphenyl (329
mg, 1.10 mmol) and quinoline (1 mL) was heated at 60-70°
C. for 12 hrs. The resulted mixture was washed with diethyl
ether and then dissolved in water (30 mL). The aqueous
solution was extracted with ethyl acetate (30 mLx3). Water
was removed by lyophilization to afford 328 mg of the title
compound. Yield: 70%. 1 H NMR (300 MHz, CDC1 3 ) o 2.49
(m, 2H), 2.84 (t, 1=6.3 Hz, 2H), 5.67 (t, 1=7.2 Hz, 2H),
7.22-7.62 (m, 9H), 7.93 (t, 1=7.5 Hz, lH), 8.10-8.21 (m,
2H), 8.34 (d, 1=7.5 Hz, lH), 8.63 (d, 1=9.0 Hz, lH), 9.11 (d,
1=8.1 Hz, lH), 10.60 (d, 1=5.4 Hz, lH) ppm; 13 C NMR (75
MHz, CDC1 3 ) o 17.1, 29.1, 57.0, 82.2, 88.4, 118.4, 121.8,
122.5, 126.9, 127.7, 128.9, 130.0, 130.2, 131.2, 131.9,
136.2, 137.8, 140.0, 140.7, 147.5, 150.5 ppm.
Example 42

~~~

Br

e

Y"

Synthesis of compound 2-[5-(1,1 '-biphenyl-4-yl)pent-4-ynyl]-isoquinolinium bromide

Br

50

A mixture of 4-(5-bromo-1-pentynl)-1,1'-biphenyl (360
mg, 1.20 mmol) and 3,5-lutidine (1 mL) was heated at
60-70° C. for 12 hrs. The resulted mixture was washed with
diethyl ether and then dissolved in water (15 mL). The
aqueous solution was extracted with diethyl ether (30
mLx3). Water was removed by lyophilization to afford 439
mg of the title compound. Yield: 90%. 1 H NMR (300 MHz,
CDC1 3 ) o 2.43 (m, 2H), 2.54 (s, 6H), 2.67 (t, 1=6.6 Hz, 2H),
5.10 (t, 1=6.9 Hz, 2H), 7.30-7.60 (m, 9H), 7.90 (s, lH), 9.24
(s, 2H) ppm; 13 C NMR (75 MHz, CDC1 3 ) o16.8, 18.8, 30.4,
60.7, 82.3, 88.1, 122.0, 127.0, 127.8, 129.0, 132.0, 138.9,
140.1, 140.8, 142.1, 146.4 ppm.

55
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A mixture of 4-(5-bromo-1-pentynl)-1,1'-biphenyl (325
mg, 1.09 mmol) and isoquinoline (1 mL) was heated at
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60-70° C. for 12 hrs. The resulted mixture was washed with
diethyl ether and then dissolved in water (30 mL). The
aqueous solution was extracted with ethyl acetate (30
mLx3). Water was removed by lyophilization to afford 340
mg of the title compound. Yield: 73%. 1 H NMR (300 MHz,
CDC1 3 ) o2.51 (m, 2H), 2.72 (t, 1=6.3 Hz, 2H), 5.34 (t, 1=6.6
Hz, 2H), 7.16 (d, 1=8.7 Hz, lH), 7.30-7.57 (m, 9H), 7.88 (m,
2H), 8.01 (d, 1=3.9 Hz, lH), 8.29 (d, 1=6.6 Hz, lH), 8.69 (d,
1=8.4 Hz, lH), 8.87 (d, 1=6.6 Hz, lH), 11.14 (s, lH) ppm;
13
C NMR (75 MHz, CDC1 3 ) o 16.9, 30.2, 60.8, 82.3, 88.0,
121.7, 126.1, 126.8, 126.9, 127.0, 127.7, 127.9, 128.9,
131.26, 131.32, 131.8, 134.6, 137.0, 140.1, 140.5, 150.9
ppm.

-continued

5

Br
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Example 43
Synthesis of compound 1-[5-(1,1'-biphenyl-4-yl)pent-4-ynyl]-3-butyl-pyridinium bromide

15

20

Br

-

25
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Br
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e

A mixture of 4-(5-bromo-1-pentynl)-1,1'-biphenyl (207
mg, 0.69 mmol) and 3-phenylpyridine (0.4 mL) was heated
at 60-70° C. for 12 hrs. The resulted mixture was washed
with diethyl ether, and then dissolved in water (30 mL). The
aqueous solution was extracted with ethyl acetate (30
mLx5). Water was removed by lyophilization to afford 206
mg of the title compound. Yield: 66%. 1 H NMR (300 MHz,
CD30D) o 2.37 (m, 2H), 2.67 (t, 1=6.3 Hz, 2H), 4.93 (t,
1=6.9 Hz, 2H), 7.18-7.59 (m, 12H), 7.74 (m, 2H), 8.09 (dd,
1=8.1, 6.0 Hz, lH), 8.65 (d, 1=8.1 Hz, lH), 9.05 (d, 1=5.7
Hz, lH), 9.46 (s, lH) ppm; 13 C NMR (75 MHz, CD30D) o
17.5, 30.9, 62.6, 82.9, 89.2, 123.2, 127.7, 128.5, 128.7,
129.4, 130.0, 130.6, 131.4, 133.1, 134.2, 141.0, 141.6,
142.3, 144.0, 144.2 ppm.
Example 45
Synthesis of compound 1-[5-(1,1'-biphenyl-4-yl)pent-4-ynyl]-1-pyridinium bromide

35

A mixture of 4-(5-bromo-1-pentynl)-1,1'-biphenyl (254
mg, 0.85 mmol) and 3-n-butylpyridine (0.5 mL) was heated
at 60-70° C. for 12 hrs. The resulted mixture was washed
with diethyl ether and then dissolved in water (20 mL). The
aqueous solution was extracted with ethyl acetate (30
mLx3). Water was removed by lyophilization to afford 263
mg of the title compound. Yield: 71%. 1 H NMR (300 MHz,
CDC1 3 ) o 0.91 (t, 1=7.2 Hz, 3H), 1.36 (m, 2H), 1.63 (m, 2H),
2.44 (m, 2H), 2.67 (t, 1=6.6 Hz, 2H), 2.84 (t, 1=7.8 Hz, 2H),
5.22 (t, 1=6.9 Hz, 2H), 7.28-7.63 (m, 9H), 8.04 (dd, 1=7.8,
6.0 Hz, lH), 8.17 (d, 1=8.1 Hz, lH), 9.39 (s, lH), 9.49 (d,
1=5.7 Hz, lH) ppm; 13 C NMR (75 MHz, CDC1 3 ) o 14.0,
16.7, 22.4, 30.5, 32.5, 32.6, 60.9, 82.4, 88.0, 121.9, 126.9,
127.7, 128.0, 128.9, 132.0, 140.1, 140.8, 142.9, 144.2,
144.3, 144.9 ppm.
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Example 44
Synthesis of compound 1-[5-(1,1'-biphenyl-4-yl)pent -4-yny1]-3-pheny1-pyridinium bromide

Br

55

60

65

A mixture of 4-(5-bromo-1-pentynl)-1,1'-biphenyl (162
mg, 0.54 mmol) and pyridine (1 mL) was heated at 60-70°
C. for 12 hrs. The resulted mixture was washed with diethyl
ether and then dissolved in water (10 mL). The aqueous
solution was extracted with ethyl acetate (30 mLx3). Water
was removed by lyophilization to afford 195 mg of the title
compound. Yield: 95%. 1 H NMR (300 MHz, CDC1 3 ) o 2.42
(m, 2H), 2.67 (t, 1=6.6 Hz, 2H), 5.21 (t, 1=6.9 Hz, 2H),
7.23-7.62 (m, 9H), 8.10 (t, 1=6.9 Hz, 2H), 8.43 (t, 1=7.8 Hz,
2H), 9.64 (d, 1=6.0 Hz, 2H) ppm; 13 C NMR (75 MHz,
CDC1 3 ) o 16.7, 30.5, 60.9, 82.3, 87.8, 121.8, 126.8, 127.6,
128.4, 128.8, 132.0, 139.9, 140.6, 145.27, 145.32 ppm.
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Example 46

phy (hexanes:ethylacetate 30:1) to afford 4.18 g of the title
compound. Yield: 99%. 1 H NMR (300 MHz, CDC1 3 ) o1.52
(m, 2H), 1.67 (m, 2H), 1.91 (m, 2H), 2.67 (t, 1=7.5 Hz, 2H),
3.41 (t, 1=6.9 Hz, 2H), 7.21-7.60 (m, 9H) ppm; 13 C NMR
(75 MHz, CDC1 3 ) o 28.2, 30.9, 33.0, 34.1, 35.6, 127.1,
127.2, 128.8, 128.9, 138.8, 141.2, 141.5 ppm.

Synthesis of compound [1,1'-biphenyl]-4-pentanol
5

OH

Example 48

-

Synthesis of compound 1-[5-(1,1'-biphenyl-4-yl)pentyl]-2-methyl-pyridinium bromide

10

OH

15

Br

-

20

5-(1 ,1 '-biphenyl-4-yl)-4-pentyn-1-ol (3.89 g, 16.46
mmol) was dissolved in methanol (30 mL), and 10% Pd!C
(2.5% w/w) was added. The resulting mixture was hydrogenated on a Parr hydrogenation apparatus (45 psi) for 4 hrs. 25
The catalyst was removed by filtration through a Celite pad.
The filter cake was rinsed with methanol, and the combined
organic liquors were concentrated under reduced pressure.
The crude product was purified by colunm chromatography
A mixture of 4-(5-bromopentyl)-1,1'-biphenyl (358 mg,
30
(hexanes:ethyl acetate 1:1) to afford 3.48 g of the title
1.18 mmol) and 2-picoline (1 mL) was heated at 60-70° C.
1
compound. Yield: 88%. H NMR (300 MHz, CDC1 3 ) o
for 12 hrs. The resulting mixture was washed with diethyl
1.35-1.48 (m, 3H), 1.55-1.74 (m, 4H), 2.66 (t, 1=7.5 Hz,
ether and then dissolved in water (15 mL). The aqueous
2H), 3.64 (t, 1=6.6 Hz, 2H), 7.21-7.60 (m, 9H) ppm; 13 C
solution was extracted with diethyl ether (30 mLx3). Water
NMR (75 MHz, CDC1 3 ) o 25.7, 31.5, 32.9, 35.8, 63.1, 35 was removed by lyophilization to afford 393 mg of the title
127.08, 127.13, 128.8, 128.9, 138.7, 141.2, 141.8 ppm.
compound. Yield: 84%. 1 H NMR (300 MHz, CDC1 3 ) o1.53
(m, 2H), 1.71 (m, 2H), 1.95 (m, 2H), 2.65 (t, 1=7.5 Hz, 2H),
Example 47
2.92 (s, 3H), 4.83 (t, 1=8.1 Hz, 2H), 7.20-7.60 (m, 9H),
7.89-8.02 (m, 2H), 8.38 (d, 1=7.5 Hz, lH), 9.53 (d, 1=6.0 Hz,
13
Synthesis of compound
C NMR (75 MHz, CDC1 3 ) o 20.9, 25.9, 30.6,
40 lH) ppm;
4-(5-bromopentyl)-1 ,1 '-biphenyl
30.8, 35.2, 58.3, 126.3, 126.8, 126.9, 127.0, 128.7, 128.8,
130.3, 138.5, 140.7, 140.9, 145.2, 146.3, 154.1 ppm.
Example 49
OH

45

-

Synthesis of compound 1-[5-(1,1'-biphenyl-4-yl)pentyl]-3-methyl-pyridinium bromide

50

Br

Br

55

[1,1'-biphenyl]-4-pentanol (3.34 g, 13.90 mmol) and carbon tetrabromide (5.99 g, 18.07 mmol) were dissolved in dry
methylene chloride (20 mL) and cooled to oo C. Triphenyl
phosphine (4.98 g, 18.07 mmol) in methylene chloride (10
mL) was added dropwise, and the mixture was stirred for 1
hat oo C. The mixture was poured into hexanes (100 mL)
and then filtered through a short silica gel colunm, washed
with ethylacetatelhexanes (1/4). The combined organic solvents were evaporated to dryness under reduced pressure.
The resulting residue was purified by colunm chromatogra-

-
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65

A mixture of 4-(5-bromopentyl)-1,1'-biphenyl (358 mg,
1.18 mmol) and 3-picoline (1 mL) was heated at 60-70° C.
for 12 hrs. The resulted mixture was washed with diethyl
ether and then dissolved in water (15 mL). The aqueous
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solution was extracted with diethyl ether (30 mLx3). Water
was removed by lyophilization to afford 421 mg of the title
compound. Yield: 90%. 1 H NMR (300 MHz, CDC1 3 ) o1.45
(m, 2H), 1.70 (m, 2H), 2.08 (m, 2H), 2.59 (s, 3H), 2.63 (t,
1=7.5 Hz, 2H), 4.92 (t, 1=7.5 Hz, 2H), 7.18-7.58 (m, 9H),
7.94 (t, 1=7.2 Hz, lH), 8.17 (d, 1=8.1 Hz, lH), 9.26 (d, 1=6.3
Hz, lH), 9.46 (s, lH) ppm; 13 C NMR (75 MHz, CDC1 3 ) o
18.8, 25.7, 30.7, 31.9, 35.2, 61.5, 126.8, 126.9, 127.0, 127.7,
128.3, 128.7, 128.8, 138.5, 139.5, 140.7, 141.1, 142.1,
144.5, 145.5 ppm.

A mixture of 4-(5-bromopentyl)-1,1'-biphenyl (331 mg,
1.09 mmol) and 2,4-lutidine (1 mL) was heated at 60-70° C.
for 12 hrs. The resulted mixture was washed with diethyl
ether and then dissolved in water (15 mL). The aqueous
solution was extracted with diethyl ether (30 mLx3). Water
was removed by lyophilization to afford 342 mg of the title
compound. Yield: 77%. 1 H NMR (300 MHz, CDC1 3 ) o1.51
(m, 2H), 1.71 (m, 2H), 1.92 (m, 2H), 2.55 (s, 3H), 2.65 (t,
1=7.8 Hz, 2H), 2.84 (s, 3H), 4.73 (t, 1=7.8 Hz, 2H), 7.207.75 (m, llH), 9.31 (d, 1=6.3 Hz, lH) ppm; 13 C NMR (75
MHz, CDC1 3 ) o 20.1, 22.0, 25.8, 30.5, 30.8, 35.2, 57.4,
126.7, 126.9, 127.0, 128.2, 128.6, 128.8, 130.4, 138.5,
140.7, 140.9, 145.4, 152.8, 158.4 ppm.

5
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Example 50
Synthesis of compound 1-[5-(1,1'-biphenyl-4-yl)pentyl]-4-methyl-pyridinium bromide

Example 52
15

Synthesis of compound 1-[5-(1,1'-biphenyl-4-yl)pentyl]-3,4-dimethyl-pyridinium bromide

Br
--

20

Br

--
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A mixture of 4-(5-bromopentyl)-1,1'-biphenyl (348 mg,
1.15 mmol) and 4-picoline (1 mL) was heated at 60-70° C.
for 12 hrs. The resulted mixture was washed with diethyl
ether and then dissolved in water (15 mL). The aqueous
solution was extracted with diethyl ether (30 mLx3). Water
was removed by lyophilization to afford 391 mg of the title
compound. Yield: 86%. 1 H NMR (300 MHz, CDC1 3 ) o 1.42
(m, 2H), 1.69 (m, 2H), 2.04 (m, 2H), 2.57 (s, 3H), 2.62 (t,
1=7.2 Hz, 2H), 4.85 (t, 1=7.2 Hz, 2H), 7.15-7.62 (m, 9H),
7.82 (d, 1=6.0 Hz, 2H), 9.25 (d, 1=6.0 Hz, 2H) ppm; 13 C
NMR (75 MHz, CDC1 3 ) o 22.3, 25.5, 30.7, 31.6, 35.2, 61.0,
126.8, 126.9, 127.1, 128.7, 128.8, 128.9, 138.5, 140.7,
141.1, 144.0, 158.7 ppm.

35
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Example 51

A mixture of 4-(5-bromopentyl)-1,1'-biphenyl (322 mg,
1.06 mmol) and 3,4-lutidine (1 mL) was heated at 60-70° C.
for 12 hrs. The resulted mixture was washed with diethyl
ether and then dissolved in water (15 mL). The aqueous
solution was extracted with diethyl ether (30 mLx3). Water
was removed by lyophilization to afford 380 mg of the title
compound. Yield: 87%. 1 H NMR (300 MHz, CDC1 3 ) o 1.43
(m, 2H), 1.69 (m, 2H), 2.05 (m, 2H), 2.46 (s, 3H), 2.48 (s,
3H), 2.62 (t, 1=7.5 Hz, 2H), 4.82 (t, 1=7.2 Hz, 2H), 7.18-7.58
(m, 9H), 7.76 (d, 1=6.3 Hz, lH), 9.07 (d, 1=6.3 Hz, lH), 9.29
(s, lH) ppm; 13 C NMR (75 MHz, CDC1 3 ) o17.1, 20.4, 25.6,
30.7, 31.7, 35.2, 60.7, 126.8, 126.9, 127.0, 128.4, 128.7,
128.8, 138.2, 138.5, 140.7, 141.1, 141.7, 143.3, 157.4 ppm.
Example 53

Synthesis of compound 1-[5-(1,1'-biphenyl-4-yl)pentyl]-2,4-dimethyl-pyridinium bromide

Synthesis of compound 1-[5-(1,1'-biphenyl-4-yl)pentyl]-3,5-dimethyl-pyridinium bromide
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A mixture of 4-(5-bromopentyl)-1,1'-biphenyl (352 mg,
1.16 mmol) and 3,5-lutidine (1 mL) was heated at 60-70° C.
for 12 hrs. The resulting mixture was washed with diethyl
ether and then dissolved in water (15 mL). The aqueous
solution was extracted with diethyl ether (30 mLx3). Water
was removed by lyophilization to afford 406 mg of the title
compound. Yield: 85%. 1 H NMR (300 MHz, CDC1 3 ) o 1.45
(m, 2H), 1.70 (m, 2H), 2.08 (m, 2H), 2.53 (s, 6H), 2.63 (t,
1=7.8 Hz, 2H), 4.84 (t, 1=7.5 Hz, 2H), 7.18-7.58 (m, 9H),
7.93 (s, lH), 9.21 (s, lH) ppm; 13 C NMR (75 MHz, CDC1 3 )
0 18.6, 25.8, 30.8, 31.9, 35.2, 61.3, 126.8, 126.9, 127.0,
128.7, 128.8, 138.4, 138.7, 140.7, 141.1, 141.7, 146.0 ppm.

-continued

Example 54
Synthesis of compound 1-[5-(1,1'-biphenyl-4-yl)pentyl]-quinolinium bromide

--

Br
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N
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A mixture of 4-(5-bromopentyl)-1,1'-biphenyl (322 mg,
1.06 mmol) and isoquinoline (1 mL) was heated at 60-70° C.
for 12 hrs. The resulted mixture was washed with diethyl
ether and then dissolved in water (30 mL). The aqueous
15 solution was extracted with ethyl acetate (30 mLx5). Water
was removed by lyophilization to afford 278 mg of the title
compound. Yield: 61%. 1 H NMR (300 MHz, CDC1 3 ) o 1.47
(m, 2H), 1.70 (m, 2H), 2.17 (m, 2H), 2.61 (t, 1=7.5 Hz, 2H),
5.07 (t, 1=7.5 Hz, 2H), 7.14-7.55 (m, 9H), 7.86 (m, lH), 8.05
20
(m, 2H), 8.33 (d, 1=6.9 Hz, lH), 8.70 (d, 1=8.1 Hz, lH), 8.79
(dd, 1=6.9, 0.6 Hz, lH), 10.93 (s, lH) ppm; 13 C NMR (75
MHz, CDC1 3 ) o 25.7, 30.7, 31.7, 35.2, 61.5, 126.3, 126.8,
126.9, 127.0, 127.7, 128.7, 128.8, 131.15, 131.22, 134.4,
25 136.9, 137.2, 138.5, 140.8, 141.0, 150.1 ppm.
Example 56
30

Synthesis of compound 1-[5-(1,1'-biphenyl-4-yl)penty1]-3 -buty1-pyridinium bromide

+

#
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A mixture of 4-(5-bromopentyl)-1,1'-biphenyl (328 mg,
1.08 mmol) and quinoline (1 mL) was heated at 60-70° C.
for 12 hrs. The resulting mixture was washed with diethyl
ether and then dissolved in water (30 mL). The aqueous
solution was extracted with ethyl acetate (30 mLx5). Water
was removed by lyophilization to afford 297 mg of the title
compound. Yield: 64%. 1 H NMR (300 MHz, CDC1 3 ) o 1.58
(m, 2H), 1.70 (m, 2H), 2.13 (m, 2H), 2.62 (t, 1=7.5 Hz, 2H),
5.37 (t, 1=7.8 Hz, 2H), 7.14-7.58 (m, 9H), 7.92 (d, 1=7.5 Hz,
lH), 8.17 (m, 2H), 8.36 (m, 2H), 9.13 (d, 1=8.4 Hz, lH),
10.33 (d, 1=5.4 Hz, lH) ppm; 13 C NMR (75 MHz, CDC1 3 )
0 26.1, 30.3, 30.9, 35.2, 58.1, 118.3, 122.5, 126.8, 126.9,
127.1, 128.7, 128.8, 129.9, 130.1, 131.1, 136.0, 137.5,
138.5, 140.7, 141.0, 147.3, 150.1 ppm.
Example 55
55

Synthesis of compound 2-[5-(1,1'-biphenyl-4-yl)penty1]-isoquinolinium bromide

60

Br
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A mixture of 4-(5-bromopentyl)-1,1'-biphenyl (360 mg,
1.19 mmol) and 4-n-butylpyridine (0.5 mL) was heated at
60-70° C. for 12 hrs. The resulting mixture was washed with
diethyl ether and then dissolved in water (15 mL). The
aqueous solution was extracted with ethyl acetate (30
mLx3). Water was removed by lyophilization to afford 377
mg of the title compound. Yield: 72%. 1 H NMR (300 MHz,
CDC1 3 ) o 0.92 (t, 1=7.2 Hz, 3H), 1.29-1.53 (m, 4H), 1.601.80 (m, 4H), 2.08 (m, 2H), 2.63 (t, 1=7.5 Hz, 2H), 2.85 (t,
1=7.8 Hz, 2H), 4.94 (t, 1=7.5 Hz, 2H), 7.18-7.60 (m, 9H),
8.00 (t, 1=7.2 Hz, lH), 8.16 (d, 1=8.1 Hz, lH), 9.29 (d, 1=6.0
Hz, lH), 9.30 (s, lH) ppm; 13 C NMR (75 MHz, CDC1 3 ) o
13.9, 22.3, 25.7, 30.8, 32.0, 32.5, 32.6, 35.2, 61.7, 126.8,
127.0, 127.1, 128.0, 128.8, 128.9, 138.6, 140.8, 141.1,
142.5, 144.0, 144.1, 144.6 ppm.
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Example 57

-continued

~OH

Synthesis of compound
1-[ 5-(1, 1'-biphenyl-4-yl)-pentyl]-pyridinium
bromide

Br

Sonagashira
Coupling

-

OH

10

~

+R

I_

N~
Br

A mixture of 4-(5-bromopentyl)-1,1'-biphenyl (335 mg,
1.10 mmol) and pyridine (1 mL) was heated at 60-70° C. for
12 hrs. The resulted mixture was washed with diethyl ether
and then dissolved in water (15 mL). The aqueous solution
was extracted with diethyl ether (30 mLx3). Water was
removed by lyophilization to afford 381 mg of the title
compound. Yield: 90%. 1 H NMR (300 MHz, CDC1 3 ) ll1.44
(m, 2H), 1.69 (m, 2H), 2.07 (m, 2H), 2.62 (t, 1=7.5 Hz, 2H),
4.96 (t, 1=7.5 Hz, 2H), 7.15-7.60 (m, 9H), 8.06 (t, 1=6.9 Hz,
2H), 8.42 (d, 1=7.8 Hz, lH), 9.48 (d, 1=6.0 Hz, 2H) ppm; 13 C
NMR (75 MHz, CDC1 3 ) ll25.6, 30.7, 31.9, 35.2, 61.8, 126.8,
127.0, 127.1, 128.4, 128.8, 128.9, 138.6, 140.8, 141.0, 145.0
ppm.
Example 58
Synthesis and Structures of Mono-Quaternary
Ammonium Compounds Containing
Phenylene-Acetylenic Moieties in theN-Alkyl
Substituent

ZZ-1-71A

ZZ-1-71C

ZZ-1-71B

30

35co
ZZ-1-71D

ZZ-1-71E

ZZ-1-71F

ZZ-1-71H

40
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~Br

Synthesis and Structures of Mono-Quaternary
Ammonium Compounds Containing
Biphenylene-Acetylenic or Biphenylene-Alkylenic
Moieties in theN-Alkyl Substituent
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N~

Br

e

Br
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N~

A

Br
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+R

N~

B
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I
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t-R

1.

N~

A
B

A

GZ·565A
GZ·573A

GZ·565B
GZ·573B

GZ·567C
GZ·575C

B

GZ·568B

GZ·568A
GZ·576A

GZ·566B
GZ·574B

GZ·566A
GZ·574·A

GZ·565C
GZ·573C

GZ·567A
GZ·575A

GZ·566C
GZ·574C

GZ·568C
GZ·576B

Example 60
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Synthesis and Structures of Mono-Quaternary
Ammonium Compounds Containing a Terminal
3-Pyridinyl Moiety

()

GZ·567B
GZ·575B

QVCX
ZZ·lAOA

#

ZZ·lAOC

ZZ·lAOB

1 ,ll·dibromoundecane

LDA

N

Br ()_R

Nv

ZZ·lAOD

35
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ZZ-1-40H
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t-R

N~

n rrn
~~ ~v
ZZ·1·77A

OC

N

ZZ·1·77D

ZZ·1·77E

45
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ZZ·1·77F

Example 61
55

Synthesis and Structures of Oxa Analogs of
Mono-Quaternary Ammonium Compounds
60

~o/'-,./ 0 ~0H

(),_R

~o~o~clNV

N

ZZ-1-40!

ZZ-1-40J

Example 62

ZZ·1·77C

~ ~N
r~ lNJ 1

ZZ·lAOG

40

~~Br

ZZ·1·77B

ZZ·lAOF
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N

~

ZZ·lAOE
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Method for the In Vitro Inhibition of [3 H]Nicotine
Binding and [3 H]Methyllycaconitine (MLA)
Binding
Test compounds of Formula (I), representing the mono
quaternary nicotine analogs of the present invention, were
evaluated to determine the effect of a test compound on
nicotine-binding and methyllycaconitine-binding mediated
by nicotine acetylcholine receptors. Table 1 of provides the
results of these binding assays.
Whole brain, excluding cortex and cerebellum, was
homogenized in 20 volumes of ice-cold buffer containing: 2
mM HEPES, 11.8 mM NaCl, 0.48 mM KCl, 0.25 mM
CaC1 2 , and 0.12 mM MgS04 , pH 7.5. Homogenate was
centrifuged (25,000 g, 15 min, 4° C.). Pellets were resuspended in 20 volumes of buffer and incubated at 37° C., for
10 min, cooled to 4° C. and centrifuged (25,000 g, 15 min,
4° C.). Pellets were resuspended and centrifuged using the
same conditions. Final pellets were stored in assay buffer,
containing: 20 mM HEPES, 118 mM NaCI, 4.8 mM KCl,
2.5 mM CaC1 2 , and 1.2 mM MgS04 , pH 7.5 at -70° C. Upon
use, final pellets were resuspended in -20 volumes of assay
buffer. Samples (250 fll) contained 100-140 flg of membrane
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protein, 3 nM [3 H]nicotine or 3 nM [3 H]methyllycaconitine
samples were collected. Subsequently, S-(-)-nicotine (10
(MLA), and test compounds of Formula (I) (100 nM) in
f.LM) was added to the buffer, and an additional 12 consecuassay buffer containing 50 mM Tris. A control sample absent
tive five minute samples were collected. At the end of the
test compounds of Formula (I) was also prepared. In the
experiment, each slice was solubilized, and the [3 H] content
3
3
[ H]nicotine-binding assay and [ H]MLA-binding assay,
5 of the tissue determined.
nonspecific-binding was determined in the presence of 10
Radioactivity in the superfusate and tissue samples was
f.LM nicotine and 10 f.LM MLA, respectively. Incubations
determined by liquid scintillation spectroscopy. Fractional
proceeded for 60 min at a room temperature using 96-well
release of tritium collected in each sample was divided by
plates, and were terminated by harvesting on Unifilter-96
the total tritium present in the tissue at the time of sample
GF/B filter plates presoaked in 0.5% polyethylenimine, 10
collection, and the fractional release of tritium collected was
using a Packard FilterMate harvester. After washing 5 times
expressed as a percentage of total tritium. Basal [3 H]outflow
with 350 fll ice-cold assay buffer, the filter plates were dried
was calculated from the average of the tritium collected in
(60 min, 4° C.), bottom-sealed, and filled with Packard's
the
two five minute samples just before addition of a test
MicroScint 20 cocktail (40 fll/well). After 60 min, filter
plates were top-sealed, and levels of radioactivity were 15 compound of Formula (I). The sum of the increase in
collected tritium resulting from either exposure to a test
determined using a Packard TopCount. Protein concentracompound of Formula (I), or exposure to S(-) nicotine in the
tions were determined using the Bradford dye-binding proabsence
and presence of a test compound of Formula (I)
cedure using bovine serum albumin as a standard protein.
equaled total [3 H]overflow. [3 H]Overflow was calculated by
3
Example 63
20 subtracting the [ H]outflow during an equivalent period of
pre-stimulation from the values in samples collected during
Method for the Analysis of Rat Striatal Slices for
and after drug exposure. Inasmuch as the radio-labeled
Inhibition of Nicotine-Evoked [3 H]Neurotransmitter
compounds were not separated and identified, the tritium
Release
collected in superfusate is referred to as either [3 H]outflow
3
3
3
25 or [ H]overflow, rather than as [ H]DA. [ H]Overflow priRat striatal slices (500 f.tm thickness, 6-8 mg wet weight)
marily represents [3 H]DA in the presence of nomifensine
were incubated for 30 minutes in Krebs buffer (118 mM
and pargyline in the superfusion buffer.
NaCl, 4.7 mM KCl, 1.2 mM MgC1 2 , 1.0 mM NaH 2 P04 , 1.3
The mono quaternary analogs of Formula (I) were evalumM CaC1 2 , 11.1 mM glucose, 25 mM NaHC0 3 , 0.11 mM
ated for their ability to evoke [3 H]DA release from rat
L-ascorbic acid, and 0.004 mM disodium EDTA at pH 7.4, 30 striatal slices. In addition, the classical competitive nicotinic
and saturated with 95% 0i5% C0 2 ) in a metabolic shaker
antagonist DH~E was also examined in this assay for
at 34 o C. Slices were rinsed with 15 mL of fresh buffer, and
comparison. None of the compounds examined had any
were incubated for an additional 30 minutes in fresh buffer
significant [3 H]DA releasing properties in this assay in the
concentration range tested.
containing 0.1 f.LM [3 H]dopamine (DA; 6 slices/3 mL).
The quaternary analogs of Formula (I) were also evaluSubsequently, slices were rinsed with 15 mL of fresh buffer 35
and transferred to a glass superfusion chamber. Slices were
ated for their ability to inhibit NIC-evoked [3 H]DA release.
superfused (1.0 mL/min) for 60 minutes with Krebs buffer
In these experiments, the striatal slices were superfused for
60 minutes with 100 nM concentration of the quaternary
containing nomifensine ( 10 f.LM) and pargyline ( 10 f.LM), and
maintained at 34° C., pH 7.4, with continual aeration (95%
analogs prior to NIC (1 0 f.LM) exposure. Antagonist activity
0 2 /5% C0 2 ). Two five minute samples (5 mL each) were 40 was evaluated by comparing the NIC-evoked [3 H]overflow
collected to determine basal outflow of [3 H]DA. The test
in the absence and presence of the analogs. The relative
compounds of Formula (I) were added to the superfusion
order of potency of the quaternary analogs of Formula (I) for
inhibition of NIC-evoked [3 H]DA release from rat striatal
buffer after the collection of the second sample, and were
slices is illustrated in Table 1.
maintained in the buffer until 12 consecutive five minute
TABLE 1
Inhibition of [3 H]NIC and [3 H]MLA Binding to Rat Striatal Nicotinic Receptors and Inhibition of Nicotine-evoked
['H) Dopamine Release from Superfused Rat Striatal Slices by Mono Quaternary Ammonium Salts of Formula (I).
Inhibition of
3
H]Nicotine
binding

Inhibition of
['H]MLA
binding

Inhibition of
Nicotine-evoked
['H]DA release

Qo/oa

Qo/oa

62o/oa

0%

0%

[

TEST COMPOUND OF FORMULA (I)

ZZ-1-49

e
Br

ZZ-1-104

e
Br

ND
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TABLE !-continued

Inhibition of [3 H]NIC and ['H]MLA Binding to Rat Striatal Nicotinic Receptors and Inhibition of Nicotine-evoked
3
[ H]Dopamine Release from Superfused Rat Striatal Slices by Mono Quaternary Ammonium Salts of Formula (I).
Inhibition of
3
[ H]MLA
binding

Inhibition of
Nicotine-evoked

TEST COMPOUND OF FORMULA (I)

Inhibition of
['H]Nicotine
binding

ZZ-1-70

0%

0%

11%

4%

2%

33%

ZZ-1-137A

0%

2%

31%

ZZ-1-47

K, > 100

Ki > 100

0%

Ki > 100

Ki;
27±11

12%

[

3

H]DA release

0

Br

ZZ-1-94

0

Br

~>

0

Br

ZZ-1-48

0

Br

( @>
ZZ-1-71

6%

3%

11%

5%

0%

58%

0%

0%

ND

0

Br

( @>
( @>
ZZ-1-76

~N

0

Br
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TABLE !-continued

Inhibition of [3 H]NIC and ['H]MLA Binding to Rat Striatal Nicotinic Receptors and Inhibition of Nicotine-evoked
3
[ H]Dopamine Release from Superfused Rat Striatal Slices by Mono Quaternary Ammonium Salts of Formula (I).

TEST COMPOUND OF FORMULA (I)

Inhibition of
3
[ H]Nicotine
binding

Inhibition of
3
[ H]MLA
binding

Inhibition of
Nicotine-evoked
3
[ H]DA release

ZZ-1-74

Ki > 100

Ki;
3.7 ± 0.3

70

Ki > 100

Ki;
14 ± 3.7

ND

ZZ-1-137F

Ki > 100

Ki;
7.2 ± 1.0

0%

ZZ-1-77

0%

0%

ND

0%

0%

64

6%

0%

19%

0%

9%

14%

0%

10%

ND

e
Br

ZZ-1-98

e
Br

HO~
®

e

Br

N

ZZ-1-101

e
Br

HO~
®

N

ZZ-1-107

-0
-0

e
Br

ZZ-1-50

e
Br

ZZ-1-73

--GN

e
Br
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TABLE !-continued

3

3

Inhibition of [ H]NIC and [ H]MLA Binding to Rat Striatal Nicotinic Receptors and Inhibition of Nicotine-evoked
3
[ H]Dopamine Release from Superfused Rat Striatal Slices by Mono Quaternary Ammonium Salts of Formula(!).

TEST COMPOUND OF FORMULA (I)

Inhibition of
3
[ H]Nicotine
binding

Inhibition of
3
[ H]MLA
binding

Inhibition of
Nicotine-evoked
3
[ H]DA release

ZZ-1-137D

3%

0%

20%

ZZ-1-97

0%

0%

ND

0%

0%

ND

0%

0%

ND

ZZ-1-137C

0%

0%

35%

GZ-565B

2%

7%

45%

ND

ND

45%

-0

e
Br

ZZ-1-72

~N

e
Br

ZZ-1-96

~N

e
Br

~N
e

Br

~

0
le#

#
GZ-573B

~

#

t)
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TABLE !-continued

Inhibition of [3 H]NIC and [3 H]MLA Binding to Rat Striatal Nicotinic Receptors and Inhibition of Nicotine-evoked
[

3

H]Dopamine Release from Superfused Rat Striatal Slices by Mono Quaternary Ammonium Salts of Formula (I).
Inhibition of
[

3

H]Nicotine

Inhibition of
[

3

H]MLA

Inhibition of
Nicotine-evoked
3

TEST COMPOUND OF FORMULA (I)

binding

binding

GZ-565A

0

2%

41%

4%

7%

55%

ND

ND

18%

0%

3%

40%

3%

51%

ND

51%

e

Br

~

#
GZ-573A

t?
t?

[

H]DA release

1(£)#

1(£)#

~

#
GZ-573C

~
1(£)#

~

#
GZ-565C

e

~

e

y

8%

y

ND

Br

1(£)#

~

#
GZ-566A

Br

~

1(£)#

#
GZ-574A

1(£)#

~

#
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TABLE !-continued

Inhibition of [3 H]NIC and ['H]MLA Binding to Rat Striatal Nicotinic Receptors and Inhibition of Nicotine-evoked
[

3

H]Dopamine Release from Superfused Rat Striatal Slices by Mono Quaternary Ammonium Salts of Formula (I).
Inhibition of
3

Inhibition of
3

Inhibition of

H]MLA
binding

Nicotine-evoked

TEST COMPOUND OF FORMULA (I)

H]Nicotine
binding

GZ-566B

0%

8%

20%

ND

ND

38%

2%

6%

5%

ND

ND

39%

1%

7%

23%

ND

ND

61%

[

[

[

3

H]DA release

~
10#

e

Br

~

#
GZ-574B

~
10#

e

Br

~

#
GZ-566C

Q
10#

e

Br

~

#
GZ-574C

Q
10#

~

#
GZ-567A

e

Br

~

#

#
GZ-575A

~

#

0
0
#

#

#
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Inhibition of [3 H]NIC and ['H]MLA Binding to Rat Striatal Nicotinic Receptors and Inhibition of Nicotine-evoked
[

3

H]Dopamine Release from Superfused Rat Striatal Slices by Mono Quaternary Ammonium Salts of Formula (I).
Inhibition of
[

3

H]Nicotine

Inhibition of
[

3

H]MLA

Inhibition of
Nicotine-evoked
3

TEST COMPOUND OF FORMULA (I)

binding

binding

GZ-567B

0%

6%

ND

0%

6%

ND

20%

6%

47%

ND

ND

51%

0%

9%

50%

ND

ND

43%

tO
tO

[

H]DA release

1(£)#

e

Br

~I

~

#
GZ-575B

1(£)#

~

~I

#
GZ-567C

e

Br

~

0

1(£)#

H3C'NQ

#
GZ-575C

0

1(£)#

~

#

H3C'NQ

GZ-568A

e

Br

GZ-576A
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3

3

Inhibition of [ H]NIC and [ H]MLA Binding to Rat Striatal Nicotinic Receptors and Inhibition of Nicotine-evoked
3
[ H]Dopamine Release from Superfused Rat Striatal Slices by Mono Quaternary Ammonium Salts of Formula(!).

TEST COMPOUND OF FORMULA (I)

Inhibition of
3
[ H]Nicotine
binding

Inhibition of
3
[ H]MLA
binding

Inhibition of
Nicotine-evoked
3
[ H]DA release

GZ-568B

8%

6%

ND

2%

6%

34%

ND

ND

30%

e

Br

~

#
GZ-568C

e

Br

~

0

10#

#
GZ-576B

0

10#

It will be appreciated that, although specific embodiments
of the invention have been described herein for purposes of
illustration, various modifications may be made without
departing from the spirit and the scope of the invention. All
such modifications and variations ore intended to be
included herein within the scope of this disclosure and the
present invention and protected by the following claims.

40

45

We claim:
1. A compound of Formula (I):

(I)

50

55

60

wherein A 1 , A 2 , A 3 , A 4 , and As are each carbon;
wherein three of R 1 , R3 , R4 , and Rs are hydrogen, alkyl,
or substituted alkyl, and
R 1 and R 2 orR2 and R3 together with the carbons to which
they are attached independently form a three- to eightmember cycloalkane, cycloalkene, aryl, heterocycle

65

with one to three hetero atoms in the ring, or substituted
heterocycle with one to three hetero atoms in the ring;
wherein Z 1 is absent or is selected from the group consisting of alkyl, substituted alkyl, cycloalkyl, alkenyl,
alkynyl, phenylene, and alkoxy;
wherein Z 2 is selected from the group consisting of
substituted alkyl, cycloalkyl, alkenyl, alkynyl, arylene,
heterocycle, substituted heterocycle, and alkoxy;
wherein Z3 is selected from propyl, butyl, hexyl, substituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heterocycle, and substituted heterocycle;
wherein x- is an inorganic or organic anion,
wherein substituted alkyl is an alkyl substituted with one
or more substituents selected from the group consisting
of hydroxy, lower-alkyl alkoxy, lower-alkyl mercapto,
halogen, trifluoromethyl, cyano, nitro, amino, carboxyl,
carbamate, sulfonyl, sulfonamide, an aryl group, and a
heterocyclic group, and
wherein substituted heterocycle is a heterocycle substituted with one or more substituents selected from the
group consisting of hydroxy, lower-alkyl alkoxy,
lower-alkyl mercapto, halogen, trifluoromethyl, cyano,
nitro, amino, carboxyl, carbamate, sulfonyl, sulfonamide, an aryl group, and a heterocyclic group.
2. The compound of claim 1, whereinA 1 , A 2 , A 3 , A 4 , and
As are carbon;
wherein R 1 is hydrogen, methyl, forms a six membered
ring with A 1 , A 2 and R 2 and with R 1 and R 2 providing
four saturated carbon atoms, or forms a phenyl group
withA 1 , A 2 and R 2 ;
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wherein R 2 is hydrogen, methyl, ethyl, butyl, phenyl,
3-hydroxypropyl, forms a six membered ring with A 1 ,
A 2 and R 1 and with R 1 and R 2 providing four saturated
carbon atoms, forms a phenyl group with A\ A 2 and
R\ forms a six membered ring withA2 , A 3 and R3 and
with R 2 and R3 providing four saturated carbon atoms,
or forms a phenyl group with A 2 , A 3 and R3 ;
wherein R3 is hydrogen, methyl, forms a six membered
ring withA2 , A 3 and R 2 and with R 2 and R3 providing
four saturated carbon atoms, or forms a phenyl group
with A 2 , A 3 and R 2 ;
wherein R4 is hydrogen or methyl;
wherein R5 is hydrogen;
wherein Z 1 is absent, butyl, but-3-ynyl, pentyl, pent-4ynyl or 2-ethoxy;
wherein Z 2 is para-phenylene, or 2-ethoxy;
wherein Z3 is propyl, butyl, but-1-ynyl, hex-1-ynyl, phenyl, or 3-pyridinyl;
and wherein X is chloride, bromide or iodide.
3. The compound of claim 1, wherein A\ A 2 , A 3 , A 4 , and
A 5 are carbon;
wherein R 1 is hydrogen, methyl, forms a six membered
ring with A\ A 2 and R 2 and with R 1 and R 2 providing
four saturated carbon atoms, or forms a phenyl group
withA 1 , A 2 and R 2 ;
wherein R 2 is hydrogen, methyl, ethyl, 3-hydroxypropyl,
forms a six membered ring with A 1 , A 2 and R 1 and with
R 1 and R 2 providing four saturated carbon atoms, forms
a phenyl group with A 1 , A 2 and R 1 , forms a six
membered ring withA2 , A 3 and R3 and with R 2 and R3
providing four saturated carbon atoms, or forms a
phenyl group with A 2 , A 3 and R3 ;
wherein R3 is hydrogen, methyl, forms a six membered
ring withA2 , A 3 and R 2 and with R 2 and R3 providing
four saturated carbon atoms, or forms a phenyl group
with A 2 , A 3 and R 2 ;
wherein R4 is hydrogen or methyl;
wherein R5 is hydrogen;
wherein Z 1 is absent, butyl, but-3-ynyl, pent-4-ynyl or
2-ethoxy;
wherein Z 2 is para-phenylene, or 2-ethoxy;
wherein Z3 is propyl, butyl, but-1-ynyl, hex-1-ynyl, phenyl, or 3-pyridinyl; and
wherein X is chloride, bromide or iodide.
4.Thecompoundofclaim1,whereinA 1 A 2 A 3 A 4 and

wherein R 1 is hydrogen, methyl, or forms a phenyl group
withA 1 , A 2 and R 2 ;
wherein R 2 is hydrogen, methyl, butyl, forms a phenyl
group with A 1 , A 2 and R 1 , or forms a pheny I group with
A 2 , A 3 and R3 ;
wherein R3 is hydrogen, methyl, or forms a phenyl group
with A 2 , A 3 and R 2 ;
wherein R4 is hydrogen or methyl;
wherein R5 is hydrogen;
wherein Z 1 is pentyl or pent-4-ynyl;
wherein Z 2 is para-phenylene;
wherein Z3 is phenyl; and
wherein X is bromide.
5. The compound of claim 1 selected from the group
consisting of:
2-[ 4-( 4-butyl-phenyl)-butyl]-5,6, 7 ,8-tetrahydro-isoquinolinium bromide;
2-[ 4-( 4-butyl-phenyl)-but-3-ynyl]-5,6, 7 ,8-tetrahydro-isoquinolinium bromide;
2- [13-(3 -pyridinyl )-tridecy1]-5,6, 7 ,8-tetrahydro-isoquinolinium bromide;
1-[5-(1,1'-biphenyl-4-yl)-pent-4-ynyl]-quinolinium bromide;
2-[ 5-(1, 1'-biphenyl-4-yl)-pent-4-ynyl]-isoquinolinium
bromide;
1-[5-(1,1'-biphenyl-4-yl)-pentyl]-quinolinium bromide;
2-[5-(1,1'-biphenyl-4-yl)-pentyl]-isoquinolinium
bromide;
2-[ 4-( 4-propyl-phenyl)-pent-4-ynyl]-5,6, 7 ,8-tetrahydroisoquinolinium bromide;
1-[2-(2-hexoxy -ethoxy)-ethy1]-5,6, 7 ,8-tetrahydro-quinolinium chloride; and
2-[2-(2-hexoxy-ethoxy)-ethyl]-5,6,7,8-tetrahydro-isoquinolinium chloride.
6. A composition comprising a pharmaceutically acceptable carrier and a compound of claim 1.
7. A composition comprising a pharmaceutically acceptable carrier and a compound of claim 2.
8. A composition comprising a pharmaceutically acceptable carrier and a compound of claim 3.
9. A composition comprising a pharmaceutically acceptable carrier and a compound of claim 4.
10. A composition comprising a pharmaceutically acceptable carrier and a compound of claim 5.

A 5 are carbon;
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